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Summary 
Cardiovascular diseases represent the main cause of mortality in industrialized countries; 
clinical manifestations include angina pectoris, myocardial infarction, and chronic coronary 
heart disease. Changes in fluid dynamics disturb the physiological functions of the vascular 
endothelium 1 and subsequent vascular remodeling accompanied by proliferation of cells and 
infiltration of inflammatory cells results in atherosclerosis within the vessel. The formation of 
atherosclerotic plaques causes a flow-limiting stenosis, thus restraining the coronary blood 
flow 2. 
The most frequently performed invasive procedure to reopen a stenotic vessel in clinics is 
percutaneous transluminal coronary angioplasty. To prevent a spontaneous occlusion and 
reduce restenosis rates, a coronary stent is deployed. However, the use of bare-metal stents 
(BMS) and drug-eluting stents (DES) is associated with two severe complications. A 
mechanical-induced injury provokes a remodeling of the arterial wall resulting in a neointima 
formation within the stented segment, namely in-stent restenosis (ISR). This has been defined 
as one major drawback of BMS. Restenosis evolves by increased vascular smooth muscle cells 
(SMC) migration and proliferation from the intimal layer of the vessel wall that ultimately 
obstruct the vessel lumen. Even if the use of DES reduces the incidence of ISR, the unspecific 
cytotoxicity of the loaded substances is believed to promote the development of the rare but 
more severe complication, known as late stent-thrombosis (LST) 3. Based on the current 
understanding, a permanent inhibition of endothelial cell (EC) proliferation and migration 
hampers the re-endothelialization of the stent struts. Additionally, a hypersensitive reaction to 
the stent material and polymer supports the development of thrombosis. 
Considering the pathophysiological basis for development of ISR and LST it seems evident that 
stent material and especially the drug coating are key features that should be modulated to 
inhibit the progressive proliferation of SMCs and to promote the re-endothelialization.  
Within the context of dual-drug technology that combines the different cellular effects of two 
compounds 4, we developed a DES with a luminal located atorvastatin and an abluminal applied 
sirolimus. This approach inhibits ISR without provoking a long-term impact on re-
endothelialization. Novel concepts predict the use of an abluminal located antiproliferative drug 
to ensure a targeted tissue release while reducing the systemic exposure 5. Based on this 
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concept, we analyzed the effects of atorvastatin and sirolimus on cellular proliferation (section 
3.1). Atorvastatin was found not to impede the antiproliferative effect of sirolimus on SMCs. 
Furthermore, atorvastatin revealed a less pronounced effect on ECs proliferation. Given these 
results, re-endothelialization may be less impaired by using dual DES with an 
abluminal/luminal coating strategy. 
From a pharmacological point of view there are two different strategies to improve cell-specific 
effects of chemotherapeutics which includes identifying of cellular targets and modulating the 
pharmacokinetics of candidate drugs. One mechanism that contributes to the drug`s 
pharmacokinetic profile is the expression of drug transporters that mediate the uptake or efflux 
of compounds 6. Specifically, the expression of efflux transporters, including P-glycoprotein, 
modulates the biological cellular activity of chemotherapeutics thus hampering the therapeutic 
effect 7. The uptake transporter OCT1 has been shown to transport a variety of substances 
including the established DES-compound paclitaxel 8. Therefore, we tested whether an 
adenoviral-induced overexpression of OCT1 using the SMC-specific promotor of transgelin 
(SM22α) would enhance the antiproliferative effects of paclitaxel in vascular SMCs (section 
3.2). First, the activity of SM22α was assessed in various cell types; a muscle cell-specific 
expression was demonstrated. The activity of OCT1 was then compared in adenoviral infected 
ECs and SMCs, with a higher accumulation of OCT1 substrates found in SMCs. To test the 
findings from the concept study relating to cell-specific drug effects, we studied the impact of 
paclitaxel treatment of ECs and SMCs, finding a significantly increased effect in SMCs. These 
results suggest that cell-specific expression of transport proteins serves as a mechanism for 
producing a selective effect on target cells. 
Another approach to improve the outcome of DES is the use of drugs that show benefits in the 
treatment of atherosclerosis. Since pleiotropic activities of statins were associated with a high 
potential in restenosis reduction after systemic therapy 9, 10, statins were suggested as suitable 
drug candidates for local application. Following data that shows a high impact of cerivastatin 
in inhibiting SMCs proliferation and neointima formation without impairing ECs cellular 
behavior 11, 12, we studied which cellular mechanism may account for the cell-specific activity 
(section 3.3). Endothelial cells and SMCs were treated with different statins, with atorvastatin 
especially presenting an SMC-specific inhibition of proliferation. Quantifying the expression 
of the primary drug target revealed comparable levels of HMG-CoA reductase mRNA and 
protein expression, leading to the assumption that pharmacokinetics may account for different 
cellular activity. We detected a higher accumulation of atorvastatin in SMCs; this has been 
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associated with a higher endogenous expression of OATP2B1, a high affinity transporter for 
atorvastatin 13. Adenoviral-induced overexpression of OATP2B1 supported our previous 
finding. Assuming that the expression of OATP2B1 is a determinant of drug effects in SMCs, 
we used a cell line overexpressing OATP2B1 to identify cytotoxic drugs suitable for SMC 
specific inhibition. The screening provided evidence that teniposide may be an OATP2B1 
substrate. This was supported by subsequent proliferation assays demonstrating a higher 
efficacy of teniposide on SMC proliferation in the presence of heterogeneously expressed 
OATP2B1. 
A variety of limus agents have entered clinics for local application on DES. While several drugs 
including sirolimus, zotarolimus, and everolimus demonstrated high efficiency and safety, 
some failed to do so 14. The anti-inflammatory and immunomodulatory compound 
pimecrolimus especially showed excessive neointimal growth in humans despite promising 
data from a preclinical assessment 15, 16. Nevertheless, the underlying mechanisms contributing 
to the failure of pimecrolimus eluting stents are unknown. We therefore studied the impact of 
pimecrolimus on SMCs and ECs proliferation and viability (section 3.4). According to our 
study, pimecrolimus had a cytostatic effect in both cells. Since preliminary data from an mRNA 
microarray suggested that pimecrolimus induced the expression of genes involved in the 
interferon signaling pathway, we analyzed their expression by real-time quantitative PCR. 
Importantly, pimecrolimus but not sirolimus led to an upregulation of these genes. This could 
in part be associated with inhibition of the phosphatase calcineurin, a downstream target of the 
pimecrolimus/FK506-binding protein 12-complex and known to modulate the interferon 
pathway 17. Specifically, the interaction of calcineurin with toll-like receptor 4 may modulate 
the expression of interferon-inducible genes upon pimecrolimus treatment. In accordance were 
our findings showing that silencing of the toll-like receptor 4 reduced the activation of gene 
expression. This crosstalk between the interferon and toll-like receptor 4 signaling may be a 
molecular mechanisms explaining the failure of pimecrolimus-eluting stents in clinical trials.  
SUMMARY 
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Chapter 1 
Introduction 
This chapter introduces coronary artery disease and its pathophysiological basis – namely 
atherosclerosis. Furthermore, it provides information about therapeutic strategies and highlights 
the pros and cons, and need for coronary artery stents. Finally, we offer a glimpse into novel 
approaches to improve efficacy and safety of these devices. 
1.1. Cardiovascular disease (CVD) - Coronary artery disease 
Cardiovascular diseases (CVD) represent the leading cause of mortality in developed countries. 
CVD are disorders of the heart and blood vessels including for instance cerebrovascular disease 
or coronary heart disease, also known as coronary artery disease, which is the most common 
cause of death in Europe 18. The clinical manifestations of CVD are diverse and involve stable 
and unstable angina pectoris, myocardial infarction, stroke, and chronic coronary heart disease. 
As reviewed by the American Heart Association in “Heart Disease and Stroke Statistics – 2014 
Update” the most attributable risk factors contributing to the manifestation and progression of 
CVD are high blood pressure, smoking, poor diet, insufficient physical activity, or abnormal 
blood glucose levels 19.  
The role of the vascular endothelium in CVD 
On a cellular level, various pathophysiological mechanisms are assumed to be associated with 
the development of CVD. Although blood vessels histologically consist of three layers, (1) the 
tunica intima, a monolayer of endothelial cells (EC), (2) the tunica media, mainly represented 
by smooth muscle cells (SMC), and (3) the tunica adventitia, it has become evident that ECs 
especially play a decisive role in pathogenesis of CVD (compare Figure 1a). 
Endothelial cells are not only directly exposed to blood and circulating noxious elements 20, but 
also maintain vascular homeostasis by modulating the vascular tone, controlling the transport 
of molecules and blood gases through the vascular wall, and regulating cell growth and 
inflammatory responses 21. Not surprisingly, changes in fluid dynamics or mechanical forces 
result in functional and structural alteration of the endothelial layer. The predominant stimulus 
influencing vascular homeostasis is endothelial shear stress that derives from the friction of the 
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flowing blood on the luminal surface of the arterial wall 20, 22. Disturbed or low shear stress 
induces the expression of transcription factors resulting in suppressed or induced expression of 
genes modulating cellular functions 23. In particular, in arterial regions with disturbed flow, low 
shear stress diminishes the expression and function of the endothelial nitric oxide synthase 
(eNOS) 24, thereby reducing bioavailability of nitric oxide (NO). The decrease in NO 
bioavailability substantially contributes to development and progression of CVD since NO is 
assumed to regulate activity of growth factors released from vascular cells, promote SMC-
induced vasodilatation, and protect vessels against platelet aggregation 21. In addition, NO 
exhibits anti-inflammatory properties, as it inhibits adhesion of inflammatory cells to the 
endothelial cell layer. 
Taken together, these results suggest that a functional vascular endothelium is essential for 
cardiovascular homeostasis, and endothelial dysfunction is considered an early marker for 
atherosclerosis 25, which is the pathophysiological foundation of most forms of CVD. 
1.2. Coronary atherosclerosis 
There are two terms frequently used in the context of coronary artery or vascular disease -
namely atherosclerosis and arteriosclerosis. In general, a thickening or hardening of the artery 
wall defines arteriosclerosis, which causes stiffness and a loss of elasticity. Arteriosclerosis can 
be present in every artery of the body, but is fatal when it affects the coronary arteries. The most 
common type of arteriosclerosis is atherosclerosis mainly characterized by lipid deposition in a 
focal plaque within the arterial wall. 
Atherosclerosis as an inflammatory disease 
Based on our current understanding, atherogenesis is assumed to be a multifactorial process as 
summarized by Libby et al. (illustrated in Figure 1b-d) 2. Interestingly, there was a change in 
understanding of the pathophysiology of atherosclerosis at the beginning of the 21st century. 
Previously, atherosclerosis was considered a degenerative disease, but as inflammation has 
been identified as an essential driving force, atherosclerosis is nowadays classified as an 
inflammatory disease 26. Although it is generally accepted that risk factors including 
hypertension and hyperlipidemia play a role in the initiation and progression of atherosclerosis, 
atherosclerotic plaques predominantly arise in sites of disturbed blood flow 27. Based on the 
“response-to-injury” hypothesis established by Ross et al., changes in blood flow induce a 
sequence of cellular alterations where inflammation is a substantial factor contributing to all 
stages of the progressing disease 24, 28. The complex interplay of resting cells (EC and SMC) 
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and cells circulating in the blood (thrombocytes, lymphocytes, monocytes) and their secretory 
products does ultimately change the homeostasis of the balanced system.  
The recruitment of inflammatory cells in the area concerned is a major component in 
atherogenesis. Shear stress induced activation of the transcription factor nuclear factor-κB 
(NF-κB) regulates the expression of cytokines (TNFα, interleukin-1β, interferon-γ) and 
adhesion molecules including the vascular adhesion molecule 1, the intercellular adhesion 
molecule 1 and the monocyte chemoattractant protein 1 23, 29. Increased expression of these 
molecules facilitates the recruitment, attachment, and transmigration of leukocytes. 
Consequently, after transmigration in the artery wall, monocytes differentiate into macrophages 
that sustain the pro-inflammatory environment. Simultaneously, changes in the permeability of 
the endothelium allow the entry of cholesterol-containing low-density lipoproteins (LDL) that 
accumulate in the arterial wall 30. 
Figure 1. Development of atherosclerotic lesions. (A) Normal structure of an artery consisting of three different 
layers; (1) the intima containing resident smooth muscle cells and lined by an endothelial cell monolayer, (2) the 
tunica media represented by smooth muscle cells (SMCs) embedded in extracellular matrix, and (3) the tunica 
adventitia. (B) Changes in vascular homeostasis leads to an expression of adhesion molecules promoting the 
adhesion and migration of monocytes, and subsequently formation into macrophages, which accumulate LDL to 
yield foam cells. (C) SMCs from the tunica media migrate into the tunica intima and proliferate. They produce 
extracellular matrix proteins such as collagen. Extracellular lipid from dead SMC accumulate in the plaque known 
as the necrotic/lipid core. (D) Disruption of the plaque results in thrombus formation, a severe complication of 
atherosclerosis. Figure reproduced from Libby et al. 2011 2 
Activated macrophages take up the LDL particles and become so-called foam cells, whose 
accumulation reflects the histological appearance of the yellow-white fatty-streak lesions. 
Additionally, vascular SMC predominantly located in the tunica media migrate into the intima 
and proliferate. Finally, the secretion of cytokines, growth factors, and extracellular matrix 
proteins from inflammatory cells and SMC promote the formation of a plaque covered by a 
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fibrous cap. Moreover, an inefficient clearance of dead cells results in accumulation of cellular 
debris and extracellular lipid that forms a necrotic lipid-rich core within the plaque 31. 
Consequently, plaque formation causes a flow-limiting stenosis in the area concerned, which in 
turn can promote an exercise-induced myocardial ischemia, or can reduce resting coronary flow 
to produce unstable angina or myocardial infarction. Moreover, different circumstances lead to 
digestion of extracellular matrix that involves a thinning of the fibrous cap that is prone to 
rupture. Subsequently, exposed pro-coagulant material activates and aggregates thrombocytes, 
forming a thrombus on the lesion’s surface that interrupts the blood flow locally or that lodges 
in distal vessels, finally provoking embolism. 
1.3. Percutaneous coronary intervention 
Looking at the potential life-threatening consequences of atherosclerosis, therapeutic treatment 
is a prerequisite to reduce and/or prevent atherogenesis and to improve the prognosis of patients 
suffering from CVD. However, therapeutic options of atherosclerosis and its clinical 
manifestations are diverse. Avoiding risk factors such as smoking or physical inactivity and 
medical treatment of hyperlipidemia, hypercholesterolemia, diabetes, and/or high blood 
pressure are fundamental strategies to prevent atherosclerosis. 
One principle approach to treat functionally relevant vascular stenosis is the mechanical dilation 
of affected vessels by angioplasty. In 1964 Dotter and Judkins first described the successful 
transluminal treatment of stenotic femoral arteries, while thirteen years later Andreas Gruntzig 
performed the first percutaneous transluminal angioplasty (PTCA) as an invasive intervention 
in cardiology, widening an obstructed coronary blood vessel 32, 33. 
In this procedure, a catheter system consisting of a guiding and a dilatation catheter was inserted 
into the stenotic area of the coronary artery via the arteria femoralis. The balloon at the tip of 
the dilatation catheter was inflated at the side of the stenosis and pressed the atherosclerotic 
material into the vessel wall, thereby widening the lumen and reducing the clinical symptoms 
of stenosis.  
Since then the technique of transluminal angioplasty has been constantly improved and has 
become one of the most often performed invasive procedures in clinical practice. 
However, restenosis of the dilated vessels that occurs in 30 – 50% of patients limited the clinical 
success of PTCA 34-36. While acute vessel closure immediately after dilatation resulted either 
from thrombus formation or elastic recoil of the stretched area 37, restenosis occurring within 
the first months after dilatation is assumed to be associated with proliferation of intimal SMC 
and extracellular matrix remodeling at the side of the injured endothelial layer 34, 38. Based on 
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the idea that a metal scaffold inserted after the procedure of balloon angioplasty would 
mechanically prevent acute occlusion of PTCA treated vessels, the first bare metal stent (BMS), 
also known as the WALLSTENT® (Schneider, AG) was developed and implanted in a human 
coronary artery in the mid-1980s 39. 
Bare metal stents – Appearance of in-stent restenosis 
The first clinical data reported on BMS - a self-expandable stainless-steel mesh stent 
(WALLSTENT®) and a balloon-expandable metal stent (Palmaz-Schatz stent) - were promising 
39-41. Unfortunately, despite the unwanted side effect of elastic recoil mechanically prevented 
by BMS implantation, clinical trials revealed an increase in subacute thrombotic events within 
the first weeks after implantation; this could in part be reduced by antiplatelet therapy with 
small molecules such as clopidogrel 42. 
In the following years, various clinical studies further validated the improved outcome of PTCA 
followed by stent implantation 43, 44; in 1994, this finally led to the FDA approval of the balloon-
expandable Palmaz-Schatz stent developed by Johnson & Johnson.  
However, as well as thrombus formation, the occurrence of a second side effect hampered the 
clinical success of BMS. The so-called neointimal hyperplasia led to restenosis within the 
stented segment. This in-stent restenosis (ISR) occurred at rates of around 30%, varying with 
the respective stent platform that was implanted 45, 46. 
The pathophysiological mechanisms leading to ISR remain only partly understood. However, 
the most accepted explanation is an adaptation of the “response-to-injury” hypothesis 47-49. As 
recently summarized from Simard and colleagues, a mechanical disruption of the endothelial 
lining by PTCA with stent placement and subsequent inflammatory signals stimulates a 
remodeling process involving the migration and proliferation of vascular SMCs from the tunica 
media to the injured area. The secretion of extracellular matrix proteins by SMC with a synthetic 
phenotype further exacerbates neointimal growth, ultimately obstructing the vessel lumen 
(Figure 2) 49. 
In accordance with the hypothesis that endothelial injury is a stimuli for ISR, findings show 
that the intensity of neointimal proliferation of SMC is directly associated with stenting and in 
particular with the stent design 50, 51. A greater stent strut thickness, which is assumed to be 
associated with a higher degree of vascular injury results in higher restenosis rates 52. This has 
been supported by findings from a porcine model of coronary restenosis demonstrating a strong 
correlation of neointima formation with severity of vessel injury as defined by “injury scores” 
53. The denudation of the endothelium and subjacent tunica media induced greater neointima
CHAPTER 1. INTRODUCTION 
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compared to arteries where stenting only impaired the endothelium. The role of inflammation 
in the process of ISR is supported by studies showing the increase of inflammatory cells in 
neointimal regions, thereby suggesting that inflammation is a predictor of neointimal growth 54-
56. 
Figure 2. Development of in-stent restenosis after BMS implantation. (A) Atherosclerotic lesion with plaque 
development. (B) BMS implantation compresses the atherosclerotic material into the vessel wall provoking an 
injury of the endothelial cell layer. (C) Proliferation of vascular SMCs and secretion of extracellular matrix 
proteins leads to in-stent restenosis. Figure reproduced from Simard et al. 49 
Drug-eluting stents – Appearance of late stent thrombosis 
Considering that PTCA induced injury is not fully avoidable during the procedure, and 
assuming that inflammatory processes and proliferation of vascular SMCs contribute to in-stent 
restenosis, the stent material was coated with antiproliferative or immunosuppressant drugs. 
These drug-eluting coronary implants revolutionized interventional cardiology. The first 
generation of drug-eluting stents (DES) approved by the FDA were loaded with sirolimus 
(Cypher®, Cordis, Warren, New Jersey, USA) or paclitaxel (Taxus®, Boston Scientific, Natick, 
USA) on a stainless steel platform, both inhibiting the mitogen-mediated proliferation of 
vascular SMCs during neointima formation. While sirolimus inhibits the initial phase of cell 
cycle progression (G1) 57, paclitaxel directly restrains the spindle microtubule dynamics and 
therefore inhibits the mitosis phase of the cell cycle 58. The approval of these devices was based 
on data from short-term clinical trials, which evaluated the appearance of ISR and adverse 
cardiovascular events like myocardial infarction. Researchers observed restenosis rates of 
approximately 10% without adverse systemic effects normally associated with the compounds 
59-63. Even five-year follow-up studies investigating the long-term efficacy of paclitaxel- and 
sirolimus-eluting stents demonstrated a real benefit with an overall reduction of target vessel 
revascularization when compared to BMS treated patients 64, 65. 
1.3. PERCUTANEOUS CORONARY INTERVENTION
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However, despite the successful reduction of neointima formation, the increasing risk of a rare 
but more severe complication, namely late stent thrombosis (LST, > 30 days after stenting) or 
very LST (> 1 year) overshadowed the clinical success of first generation DES 66-68. Stent 
thrombosis results in an abrupt closure of the stented artery and is associated with a high risk 
for myocardial infarction and death 69, 70. One must consider that thrombotic events often 
occurred with the first DES due to premature antiplatelet therapy discontinuation. In this regard, 
the FDA prolonged antiplatelet therapy after DES placement from 3-6 months to one year 
despite this being associated with the risk of bleeding 71-73. 
Unfortunately, there is no precise understanding of the mechanisms contributing to late stent 
thrombosis but findings suggest that a combination of several factors promote its development 
49. Apart from patient- and lesion-specific factors, DES-specific characteristics lead to the
increased risk of LST including the hypersensitivity to drug coating or polymer and 
inflammatory response to stent struts 3. Nevertheless, the most attributable factor for thrombosis 
is the disturbance of endothelial cell regeneration (re-endothelialization) by the not cell-specific 
activity of the loaded compounds. Both, sirolimus and paclitaxel not only inhibit the migration 
and proliferation of SMCs but also the proliferation and viability of endothelial cells. Since 
functional vascular endothelium plays a crucial role in vascular homeostasis by preventing 
inflammation and remodeling processes, these compounds thus create a pro-thrombotic 
environment with possible fatal consequences one year after stent implantation. 
In-stent restenosis vs. late stent thrombosis 
In conclusion, the implantation of coronary devices is associated with two severe complications 
the in-stent restenosis and the late stent thrombosis. In-stent restenosis was first observed in 
patients treated with BMS (Figure 3A) 74, while late stent thrombosis is the unwanted side effect 
of DES (compare Figure 3B).  
Figure 3. Complications of Coronary Stenting. (A) Restenosis or (B) late 
stent thrombosis in a coronary artery treated with a BMS or DES, 
respectively. Figure reproduced with permission from Curfman et al.  75, 
Copyright Massachusetts Medical Society. 
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Even if the current understanding of the factors contributing to ISR and LST suggests that these 
unwanted effects are device-specific, there is an overlap. Restenosis and thrombosis affect the 
clinical outcome of both devices, but often at different time-points post stenting 76. For instance, 
it has been demonstrated that very LST occurs with a rate of 0.1% per year in patients receiving 
a BMS even though this rate is much lower than that observed for DES 77, 78. 
1.4. Current approaches for improvement of DES 
Considering the pathological basis for restenosis and stent thrombosis it seems evident that the 
stent material and/or drug coating are key features that may be improved to promote a functional 
vascular endothelium. From a pharmacological point of view, the identification of a compound 
ideally demonstrating SMC-specific antiproliferative activity appears to be a promising 
strategy. Hence, special emphasis has been placed on the improvement of coronary stents using 
novel polymers or stent materials and/or potent anti-inflammatory and antiproliferative drugs. 
Thus researchers have developed DES with (1) different stent platforms, (2) biocompatible or 
bioresorbable polymers, (3) or other compounds of the limus group, investigations that resulted 
in the development of second- and next-generation DES (see Table 1). Different randomized 
controlled clinical trials have compared the clinical outcome of these DES with the first-
generation DES or BMS. The following paragraphs elucidate these recent investigations 
focusing on stent material and compounds of the limus group and how previous research has 
led to the approaches adopted in this study. 
Investigations on stent platform and polymers 
There is emerging evidence that stent design plays a significant role in development of 
restenosis and/or thrombosis, especially since hypersensitivity reactions to the materials has 
impaired the success of coronary implants 79, 80. Current scaffolds of DES are composed of 
cobalt chromium or platinum chromium both allowing thinner stent struts with a reduction of 
local inflammatory processes and the development of overall and very LST 81-83.  
In addition, biocompatible stent platforms, especially devices that consist of the poly-L-lactic 
acid (PLLA) demonstrate good safety in coronary applications 84, 85. Moreover, inflammatory 
reactions can be reduced using bioresorbable stent platforms and/or drug-eluting polymers. 
Previous polymers eluting sirolimus or paclitaxel consisted of synthetic materials, which have 
been associated with LST 86. Immediately after drug release, the remaining polymer induces an 
inflammatory reaction as demonstrated from pathological samples of stented vessels where 
inflammatory cells appear around fragments of polymers 87. The biolimus-eluting stent Nobori® 
1.4. CURRENT APPROACHES FOR IMPROVEMENT OF DES
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consists of a stainless steel platform, biolimus and a bioresorbable polymer, which dissolves 
into carbon dioxide and water after 6 to 9 months. Studies comparing Nobori® with paclitaxel- 
or sirolimus-eluting stents have demonstrated promising results 88, 89. Consequently, stents with 
complete bioresorbable scaffold were designed. The Absorb®, a fully bioresorbable stent 
completely dissolves in 3 to 3.5 years. Although investigations yielded no significant concerns 
with the Absorb® compared to stents with durable material, a multi-center study demonstrated 
a high risk of scaffold thrombosis within the first 6 months 90, 91. Accordingly, further studies 
are warranted to elucidate whether these strategies will improve the safety and efficacy profiles 
of currently used DES. 
Table 1. Overview of former and new Drug-eluting stents and related clinical trials (small selection) 
Stent name Stent platform Polymer Drug eluted Clinical trials 
First-Generation DES 
Cypher® steel persistent sirolimus SIRIUS 
Taxus® steel persistent paclitaxel TAXUS EXPRESS® I-VI 
Second-Generation DES 
Xience V® cobalt persistent/biocompatible everolimus SPIRIT I-V, SORT-OUT 
Endeavor® cobalt persistent zotarolimus ENDEAVOR I-IV 
Next-Generation DES 
Nobori® steel bioresorbable PLA biolimus NOBORI I 
Absorb® bioresorbable 
PLA 
bioresorbable everolimus ABSORB II 
Everolimus and zotarolimus as new compounds on DES 
The efficacy and safety of a coronary device is not only influenced by the stent material, but 
also by the loaded drug. As inflammation plays a crucial role in the development of 
atherosclerosis, restenosis and thrombosis, the first DES was loaded with sirolimus, which is 
an effective immunosuppressive and antiproliferative agent that demonstrates high potential in 
restenosis reduction. Data from meta-analyses confirmed a more efficient inhibition of ISR 
compared to paclitaxel-eluting stents 92, 93. Thus, researchers evaluated the efficacy of 
sirolimus-derivatives such as everolimus and zotarolimus (Figure 4). Despite everolimus being 
commonly used as an immunosuppressant in transplantation medicine and exhibiting similar 
pharmacodynamics as sirolimus with inhibition of cell metabolism and cell proliferation by 
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blocking the cell cycle at late G1 phase, this drug has a different pharmacokinetic profile with 
higher polarity and a slightly higher lipophilic character 94, 95. Consequently, everolimus is 
assumed to exhibit enhanced cellular absorption and a longer intracellular resident time. After 
observing promising results with oral everolimus in animal studies 96, 97, a clinical evaluation 
of an everolimus-eluting stent was carried out. On the basis of results from the SPIRIT trial 
program, the FDA approved the Xience V® Stent (Abbott Laboratories, Abbott Park, IL, USA) 
in 2008. When compared to BMS or paclitaxel-eluting stents this device demonstrated 
enhanced safety with a significant risk reduction in thrombotic events even in the long-term 
follow up 98-100. A meta-analysis demonstrated increased benefits with everolimus-eluting stents 
in long-term clinical outcome with regard to stent thrombosis 101. However, when compared to 
sirolimus-eluting stents the risks for myocardial infarction or all-cause death were similar for 
both stent types. 
sirolimus/ rapamycin
everolimus zotarolimus
Figure 4. Structures of limus agents. 
Another compound of the limus group is zotarolimus, which is a semisynthetic derivative of 
sirolimus. Zotarolimus is the most lipophilic of the limus analogues synthesized to support 
higher vessel wall localization, whereby reducing systemic circulation and demonstrating a 
high impact on vascular SMC proliferation 102. Data from clinical trials comparing the efficacy 
and safety of the zotarolimus-eluting stent Endeavor® (Medtronic, Santa Rose, CA, USA) in 
humans demonstrated this stent system as a safe treatment for obstructive coronary disease 103 
with a lower incidence of restenosis compared to BMS 104. Although Endevaor® failed to 
promote an improvement in ISR reduction when compared to first-generation DES 105, 106, the 
low safety-risks enabled an FDA approval. Interestingly, myocardial infarctions and death were 
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less common with zotarolimus-eluting stents suggesting a potential benefit concerning vascular 
healing 107, 108. 
Brief summary about current approaches 
In addition to new stent materials and polymers, the loaded drug remains the main predictor for 
efficacy and safety of coronary devices. The first DES were developed using agents that mainly 
exhibited antiproliferative activity in cells. Due to safety issues associated with the lack of 
cellular specificity of the compounds, there is a need to identify drugs that specifically inhibit 
the proliferation of vascular SMCs or that restrain the inflammation that arises after stent 
deployment. Although the use of sirolimus derivatives everolimus and zotarolimus reduced the 
rates of stent thrombosis compared to first-generation DES, there is still the risk of late events 
suddenly affecting patients’ health; the development of neoatherosclerosis and associated 
incidence of late restenosis and thrombosis is a common feature in patients with late stent failure 
109. Experience has shown that it is essential to know which cellular mechanisms are responsible 
for the success or failure of a drug in stent design. For example preclinical studies with the 
limus agent tacrolimus promised a favorable outcome in patients but clinical data demonstrated 
a high restenosis rate 110-112. Following this, in vitro data investigating the efficacy of tacrolimus 
to inhibit SMCs proliferation revealed an induction of cell proliferation by tacrolimus, 
explaining the failure in clinical assessment (see chapter 1.5 anti-inflammatory compounds) 113. 
Thus, there is a need for in vitro research to identify the pharmacodynamics in cells specifically 
from the microcompartment coronary artery, which are involved in restenosis and thrombosis 
development in order to extrapolate the efficiency in vivo. 
1.5. Novel approaches for DES based on cellular determinants 
Vascular endothelial and smooth muscle cells are those cells that are mainly influenced by 
dynamic changes and injuries. Both cell types react with structural and functional alterations 
consequently leading to a remodeling of the vessel. Therefore, in drug development it is 
necessary to understand the cellular mechanisms in SMCs as well as ECs that contribute to the 
required effects, especially when a cell-specific activity is warranted. 
Dual-loading stents – A luminal/abluminal loading technology 
Since clinical data of sirolimus-eluting stents indicated strong potential, long-term safety 
concerns encouraged researchers to evaluate the effect of other compounds targeting cellular 
processes involved in ISR development. First, the efficacy of systemically applied substances 
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including antiplatelet and anticoagulant drugs, vitamins, or statins was assessed 114. This led to 
considering whether a combination of these drugs with sirolimus or paclitaxel would be useful 
for targeting different cellular functions to strengthen the efficacy in ISR reduction and to 
enhance safety of DES. Accordingly, it is important to note that the antiproliferative drug should 
be directed to the side where SMCs migrate and proliferate (abluminal). This loading 
technology ensures a more targeted tissue release as used in the biolimus-eluting Nobori® DES 
stent 115. 
Figure 5. Schematic of a dual-loading DES. The metallic scaffold is coated with a polymer integrating a luminal 
(red) bloodstream-directed compound and an abluminal (blue) vessel-wall directed drug-release. The DES is 
integrated into the endothelium. Drug release into the abluminal direction should inhibit the proliferation of intimal 
and medial smooth muscle cells. 
Antioxidants and anti-thrombotic compounds 
The stimulation of vascular SMC proliferation is amongst others achieved by oxygen free 
radicals 116. Therefore, probucol a lipid-lowering drug with antioxidant properties was tested in 
local drug delivery based on studies demonstrating a benefit of systemic probucol 117-119. In 
detail, probucol reduced inflammatory cell adhesion and inhibited stent thrombosis as well as 
neointimal hyperplasia, thereby promoting re-endothelialization in rabbit artery models. 
However, although a polymer free dual-loading DES consisting of probucol and sirolimus 
demonstrated a good efficiency and safety profile this DES failed to show enhanced clinical 
benefits 120. This was assumed to be a result of the polymer free surface 121. Currently a 
probucol-releasing anti-thrombogenic DES is under development 122. 
Another compound, which has been embedded with sirolimus in a DES, is the anti-thrombotic 
drug triflusal. In vitro release kinetics revealed an inhibition of platelet adhesion and suggested 
a release of both compounds within a time frame that favors the temporal sequence of 
thrombosis formation, inflammation, and proliferation in vivo 123. These findings are supported 
by additional in vivo studies in a porcine coronary model showing a reduction in restenosis 
when compared to controls. However, clinical data are still missing. 
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HMG-CoA reductase inhibitors – Statins 
The activity of the enzyme 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMG-CoA 
reductase) is the rate-limiting step in human cholesterol synthesis by reducing HMG-CoA to 
mevalonate. Since hypercholesterolemia is associated with the development of atherosclerosis 
and cardiovascular disease, a number of clinical trials have explored whether HMG-CoA 
reductase inhibitors, namely statins, diminish the progression of atherosclerosis and CVD 9, 10. 
Indeed, systemically administered statins reduced overall cardiovascular mortality. 
Accordingly, research that followed studied the impact of statins in patients receiving a 
coronary stent, showing lower rates of restenosis and/or thrombotic events. These findings are 
thought to be based on the “pleiotropic effects” of statins, including anti-inflammatory and anti-
thrombotic activity 124-126. Local application of statins in DES has been tested in order to avoid 
adverse events and to achieve a higher local drug concentration. Although at first in vivo data 
investigating the effect of statin-eluting stents demonstrated a positive impact on 
endothelialization compared to BMS or DES 127-129, there was no superiority compared to 
former DES with regard to neointima reduction. Nevertheless, the activity of statins specifically 
on endothelial cell regeneration is useful for dual loading-applications, for example based on 
data showing statin-induced upregulation of endothelial NO synthase activity 130. Thus, statins 
were suspected to suppress the delayed arterial healing originating from the cytotoxicity of 
limus agents. Preliminary efforts have been made testing the concomitant loading of tacrolimus 
and atorvastatin 131. Although tacrolimus alone demonstrated a pro-proliferative effect on 
vascular SMC proliferation by activation of growth factor signaling (TGF-β) 113, Giordano et 
al. detected that dual treatment of SMCs with atorvastatin suppressed the induced proliferation 
by apparently reinforcing the proper activity of tacrolimus (see also section 1.5 anti-
inflammatory compounds) 131. Furthermore, tacrolimus supplemented with atorvastatin 
enhanced endothelial cell proliferation due to increased expression of the pro-angiogenic factor 
endoglin. Nonetheless, the more potent antiproliferative compounds are sirolimus and 
everolimus. Therefore, future DES design could use these compounds as suitable drug 
candidates for concomitant use with statins. 
Smooth muscle cell-specific drug targeting 
As reviewed by Tang and Chen, the identification of SMC-specific drugs may follow different 
approaches including the identification of proteins regulating cell proliferation, or detection of 
growth factors which have differential effects on EC and SMC, and/or use of more than one 
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compound to achieve multiple function for different cells 132. In the vascular system, target 
(SMC) and non-target (EC) cells are in close vicinity thus previously used compounds failed to 
demonstrate cell-type specific efficiency. Therefore, one promising approach is the 
identification of a compound that specifically targets SMCs proliferation and/or migration 
during vascular remodeling. One example of a SMC specific drug target is the enzyme CTP 
synthase -1 that catalyzes CTP biosynthesis, which is essential for DNA and/or RNA replication 
during cell proliferation 133. Tang et al. showed that proliferating SMCs especially exhibited a 
high expression of this enzyme; and low dose inhibition of CTP synthase 1 diminishes growth 
factor induced SMC proliferation while not affecting ECs 132, 134. Similar specific effects could 
be obtained using the fatty acid oxidation inhibitor trimetazidine, which was shown to decrease 
the proliferation and migration of SMCs while exhibiting pro-proliferative effects in endothelial 
cells 135. 
Cell-specific inhibition by statins 
Despite lipid-lowering activity, statins are assumed to modulate different cellular functions 
independently from cholesterol synthesis (see Figure 6). The inhibition of small GTP-binding 
proteins (including Ras and Rho) by statins plays an especially crucial role in modulation of 
cell proliferation 136. Statins inhibit the synthesis of the isoprenoid derivatives geranylgeranyl 
pyrophosphate, subsequently suppressing the activation the GTPase Rho. If activated, Rho 
translocate to the cellular membrane. The subsequent modulation of the cyclin-dependent 
kinase inhibitor p27Kip1 promotes cell-cycle progression and proliferation of vascular SMCs 137. 
In quiescent cells, p27Kip1 is stably expressed and contributes to growth arrest by inhibition of 
cyclin/cyclin-dependent kinase complexes. Upon mitogen stimulation, p27Kip1 is down-
regulated and leads to an induction of cell cycle and proliferation. Consequently, 
overexpression of this protein attenuated neointima formation following vascular injury 138. 
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Figure 6. Pleiotropic Effects of Statins Figure reproduced and modified from Takemoto & Liao 136 
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Importantly, a previous study using cerivastatin showed differential cell proliferation in vitro, 
with more pronounced proliferation in SMCs compared to ECs 12. Further in vivo investigation 
using a porcine coronary model supported these findings. From a pharmacological point of 
view, cerivastatin treatment increased p27Kip1 levels in mitogen stimulated SMCs, an effect that 
was less pronounced in ECs. The authors assume that this cell-specificity is considered a statin 
effect since they found similar results using fluvastatin. However, the underlying mechanism 
for the SMC-specific effect remains unanswered. 
Inflammation as potent target in stent technology 
Based on current understanding, inflammatory reaction plays a significant role in the 
development of ISR. Cytokine-stimulated release from infiltrating monocytes in injured vessels 
initiates the migration and proliferation of vascular SMCs. In addition, stent thrombosis 
associated with DES deployment is a local hypersensitivity reaction accompanied by infiltration 
of T cells, leukocytes and eosinophils and is histopathological described by a persistent fibrin 
thrombus between stent and arterial wall 55, 87. As recently reviewed, although late stent 
thrombosis occurs with an incidence of 0.5% per year it is a severe complication resulting in 
acute myocardial infarction or sudden cardiac death with a mortality rate of 45% 139. It has been 
assumed that the increased endothelial tissue factor expression caused by either sirolimus or 
paclitaxel promotes the activation of the coagulation cascade 140, 141. Therefore, the use of these 
drugs is no longer reasonable. Accordingly, efforts have been made to use compounds that 
consistently exhibit anti-inflammatory effects thus inhibiting the activation and proliferation of 
inflammatory cells including T cells. 
The calcium- and calmodulin-dependent serin/threonine phosphatase calcineurin is essential for 
T cell activation (compare Figure 7). A complex interaction of antigen-presenting cells and toll-
like receptors induces the activation of calcineurin which dephosphorylates the nuclear 
transcription factor of activate T cells (NFAT). Active NFAT translocate to the nucleus and 
bind promotor elements of genes thus increasing the expression of pro-inflammatory cytokines 
including interleukin (IL)-2, IL-3, interferon-γ, and TNF-α 142. In contrast to the 
immunosuppressive activity of sirolimus achieved by the binding of mTOR, the compounds 
cyclosporine A, tacrolimus, or pimecrolimus act via inhibition of calcineurin. A comparison of 
both substance classes in vitro demonstrated a markedly smaller effect of tacrolimus on cell 
proliferation compared to sirolimus 143. Conversely, tacrolimus seemed to induce the 
proliferation of vascular SMCs by activation of growth factor signaling cascades 113. The 
discrepancy of these in vitro data is reflected in in vivo studies 110, 112. Despite the failure of 
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tacrolimus-eluting stents in a clinical study, a preclinical setting demonstrated a positive impact 
on neointima formation. Similar observations have been made studying the safety and 
efficiency of DES loaded with pimecrolimus 15, 16, 144. 
Figure 7. mTOR and calcineurin signaling in T cells The activation of calcineurin results in de-phosphorylation of NFAT 
(nuclear factor of activated T cells) and a subsequent expression of IL-2 (interleukin 2) and other cytokines. Calcineurin 
inhibitors cyclosporine and tacrolimus act by binding to their respective immunophilins and induce a blockade of IL-2 
production that inhibits T cell proliferation. The sirolimus/FKBP12 complex binds mammalian target of rapamycin (mTOR) 
subsequently inhibiting cell cycle. Figure reproduced from Dupont and Warrens 145. 
1.6. Pharmacokinetics determine pharmacodynamics 
The balancing act in drug development is to identify a compound that achieves high drug 
concentrations on the desired tissue or cellular target while avoiding adverse events often 
resulting from high systemic concentrations. This means an ideal compound applied on drug-
eluting devices should have (1) a wide therapeutic window, (2) lipophilic properties and (3) an 
appropriate tissue retention time to guarantee complete endothelialization 146. Accordingly, the 
therapeutic efficacy of DES compounds depends not only on the drug target but also on the 
pharmacokinetics in the vascular wall. Pharmacokinetics in general describes the fate of a 
compound starting from liberation, absorption, distribution, biotransformation, and excretion. 
All parameters influence the pharmacological activity of the compound as a drug, as they 
regulate its exposure to the desired tissue. In contrast, pharmacodynamics describes the relation 
between the drug concentration at its target and the drug effect; specifically, the initial 
absorption or uptake of compounds into target cells is an important step in biological drug 
activity. 
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Mechanisms of drug transport 
Endogenous substances or exogenously-administered compounds get into cells by different 
transport mechanisms depending on their structural nature. The interplay of molecular weight, 
molecular charge, and surface polarity defines cellular entry including simple diffusion, 
facilitated diffusion, and active transport. 
Impact of pharmacokinetics in DES technology 
Physiochemical properties of substances including aqueous solubility, lipophilicity or 
ionization play an important role in drug potency. Hydrophilic compounds, which are rapidly 
cleared, are differ from hydrophobic compounds that are retained within the tissue, often with 
dramatic consequences 147. A hydrophilic compound is advantageous if this drug possesses a 
small therapeutic window, thus avoiding a toxic accumulation in tissues. Contrastingly, a 
lipophilic compound is necessary to be absorbed and to maintain high doses in the right place. 
The parameters of “Lipinski´s rule of five” predict the permeability of a compound through 
biomembranes especially after oral drug delivery. It includes the number of H-bond donors and 
exceptors, molecular weight and the log P value 148. “P” describes the partition of a compound 
between two liquid phases, polar water and non-polar octanol and measures the lipophilicity of 
a compound. A log P > 5 means poor absorption or penetration through the membrane. 
Furthermore, the molecule passes over into the lipophilic membrane but will be less likely to 
pass from the membrane on the receptor side into aqueous internal layers 149. Direct comparison 
of sirolimus and paclitaxel revealed an equal lipophilic property as characterized by log P values 
of ~4.3 and ~3.2 for sirolimus or paclitaxel, respectively, which is associated with an efficient 
accumulation in the vascular wall 150. However, the effect of compounds is not exclusively due 
to the tissue distribution achieved by pharmacokinetics. Sirolimus accumulates particularly in 
the ISR-originating intima-media zone whereas paclitaxel distributes heterogeneously through 
the arterial wall, explaining the better efficacy of sirolimus 151. This has been associated with 
the different distribution of their cellular targets. The target for limus agents FKBP12 is 
abundantly expressed in SMCs and upregulated after vascular injury 152, 153. Based on the 
current understanding of ISR development, drug concentrations should be highest in the medial 
and intimal layer of the vascular wall. Nevertheless, drug transporters extend the possibilities 
for compounds to be distributed. Hence, they reduce or enhance drug absorption through the 
membranes. However, the impact of these proteins on drug absorption is not predicted by 
Lipinski´s rule of five. 
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The first identified drug transporters are members of the ATP-binding cassette superfamily 
facilitating the efflux of their substrates. More precisely, an overexpression of P-glycoprotein 
has been associated with the incidence of multidrug resistance in cancer cells to overcome 
chemoresistance 154. However, drug transporters are not exclusively expressed in malignant 
transformed tissue. Hence, they mediate absorption, elimination, and distribution of a variety 
of its substrates, thereby modulating their biological activity. 
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Chapter 2 
Aim of the thesis 
Considering the data from various clinical studies there is still a need to improve coronary stent 
technology. Although the incidence of in-stent restenosis is reduced, the cytotoxic compounds 
applied in DES induce a delayed healing characterized by incomplete strut endothelialization 69. 
Delayed arterial healing is assumed to contribute to the development of late thrombotic 
events 155. Thus, one approach is the identification of compounds, which specifically inhibit 
SMCs proliferation while not affecting ECs. 
The limus compound sirolimus has been widely used for many years as an immunosuppressive 
and antiproliferative agent in DES. It inhibits the function of mTOR, resulting in the inhibition 
of cell cycle progression 57. Statins exert pleiotropic effects including antiproliferation, anti-
inflammation, and anti-thrombosis 136. Cerivastatin and atorvastatin especially reduced the 
proliferation of vascular cells 129, 156. Additionally, atorvastatin activates NO synthesis by 
enhanced expression of the endothelial NO synthase 130, and accelerated the neointimal 
coverage and re-endothelialization if systemically-administered after sirolimus-eluting stent 
implantation in a porcine coronary model 157. 
The first aim of the present thesis is to study the effects of a concomitant treatment of sirolimus 
and atorvastatin both applied on a dual-loading DES. Stents were produced at the University of 
Rostock, Germany and analyzed with respect to the release kinetics of both drugs. The effects 
on cells are studied in vitro. Here, the impact on SMCs and ECs proliferation and viability are 
taken into consideration. 
Despite passive membrane transport induced by the lipophilic character of a xenobiotic, one 
mechanism contributing to pharmacokinetics is the expression of drug transporters that 
facilitate the transport of substrates 6. The organic cation transporters (OCT) are one subfamily 
within the superfamily group of SLC transporters. OCT1 plays a key role in drug distribution 
of exogenous and endogenous cations including paclitaxel 8. 
The aim of our second study is to analyze whether overexpression of OCT1 will enhance the 
cellular effects of paclitaxel particularly in SMCs. Therefore we used the promotor of transgelin 
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(SM22α) a commonly used marker for SMCs, which has been previously identified as a 
mechanistic tool for performing a cell-type specific overexpression of protein in a mouse 
model 158, 159. 
Cell proliferation is affected by a variety of compounds. Cerivastatin and fluvastatin 
demonstrate a more pronounced effect on SMCs compared to ECs in vitro 12. However, 
pravastatin does not share this antiproliferative activity 160. Although statins primarily target 
HMG-CoA reductase, they exert different physiochemical and pharmacokinetic properties 
including active transport or passive permeability 161. Hence, comparing all statins, especially 
different lipophilicity can account for a modulation of cellular distribution. Assuming that the 
distribution of cells of the coronary artery surrounding the drug-delivery devices also depends 
on passive diffusion or active transport, those mechanisms may significantly influence cell-type 
specificity of drugs used in DES. 
In the third part of this thesis, the impact of different statins on cell proliferation is compared, 
focusing on whether differences in pharmacodynamics or pharmacokinetics are responsible for 
the observed cellular effects. 
Inflammation characterized by an increased level of inflammatory cells and cytokines is 
believed to be the major driving force in the development of restenosis and thrombosis after 
vascular injury 162, 163. Accordingly, treating inflammation is one of the approaches in stent 
technology. First generation DES used sirolimus showing a more pronounced effect on cell 
proliferation. Hence, other limus agents including everolimus, tacrolimus or pimecrolimus were 
tested in preclinical studies. However, tacrolimus and pimecrolimus did not enter clinics due to 
failure in neointima reduction 16, 110. Since the underlying mechanism with tacrolimus was based 
on growth factor induced proliferation of SMCs, little is known about the pharmacodynamics 
of pimecrolimus in human coronary cells. 
In our final project we studied the impact of pimecrolimus on cell proliferation and viability 
of SMCs and ECs in order to identify the molecular mechanisms that may explain the observed 
clinical outcome in patients. 
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In vitro cell model – Microcompartment of the coronary artery 
In our recent work we used primary endothelial and smooth muscle cells isolated from the 
human coronary artery, namely HCAEC and HCASMC (Promocell GmbH, Heidelberg, 
Germany), characterized for their cell-specific proteins (Figure 8). Endothelial and smooth 
muscle cells, which are in close vicinity, represent the cellular part of the microcompartment 
coronary artery that is mainly involved in the development of restenosis and thrombosis after 
stenting. The effects of different compounds were studied in various assays in order to identify 
pharmacokinetics and pharmacodynamics that account for the activity of the tested substances. 
To simulate the situation in vivo before stent placement, HCAEC and HCASMC were cultured 
in a medium containing low concentrations of fetal calf serum for 24 h or 48 h, respectively. 
Thereafter cells were treated with the compounds in presence of growth factors to mimic the 
situation post stenting. Results from our in vitro studies were used to extrapolate the situation 
in vivo or to explain previous data that arised from in vivo studies. 
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Figure 8. Coronary artery. (A) Immunofluorescence of a histological section from human coronary artery. Tissue slide of 
paraffin-embedded coronary artery was stained for expression of SMC specific alpha-smooth muscle actin (α-sm-actin, green 
color) and for van Willebrand factor (vWF, red color) characteristic for ECs. Nuclei were stained with 4´,6-Diamidin-2-
phenylindol, DAPI. (400x) (B) Schematic of a human artery. Figure reproduced and modified from Libby 164. (C) 
Immunofluorescence of human coronary artery smooth muscle cells (HCASMC) and endothelial cells (HCAEC). Cells were 
stained for expression of α-sm-actin (HCASMC, green color) and vWF (HCAEC, red color). Nuclei were stained with DAPI. 
(HCASMC, 200x; HCAEC, 400x).
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Chapter 3 
Results and discussion 
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Abstract Within the context of novel stent designs we
developed a dual drug-eluting stent (DDES) with an ab-
luminally focussed release of the potent anti-proliferative
drug sirolimus and a luminally focussed release of ator-
vastatin with stabilizing effect on atherosclerotic deposits
and stimulating impact on endothelial function, both from
biodegradable poly(L-lactide)-based stent coatings. With
this concept we aim at simultaneous inhibition of in-stent
restenosis as a result of disproportionally increased smooth
muscle cell proliferation and migration as well as throm-
bosis due to failed or incomplete endothelialisation. The
especially adapted spray-coating processes allowed the
formation of smooth form-ﬁt polymer coatings at the
abluminal and luminal side with 70 % respectively 90 % of
the drug/polymer solution being deposited at the intended
stent surface. The impacts of tempering, sterilization, and
layer composition on drug release are thoroughly discussed
making use of a semi-empirical model. While tempering at
80 C seems to be necessary for the achievement of ade-
quate and sustained drug release, the coating sequence for
DDES should be rather abluminal–luminal than luminal–
abluminal, as reduction of the amount of sirolimus eluted
luminally could then potentially minimize the provocation
of endothelial dysfunction. In vitro proliferation and via-
bility assays with smooth muscle and endothelial cells
underline the high potential of the developed DDES.
1 Introduction
After entering the European market in 2002, drug-eluting
stents (DES) revolutionized the treatment of coronary
artery disease. DES are specialized vascular stents which
allow a long-term local drug delivery with the purpose to
reduce or prevent in-stent restenosis (ISR), which has been
identiﬁed as one major drawback of bare metal stents
(BMS). In this context, DES of the so called ﬁrst genera-
tion provided a controlled release of either the immuno-
suppressant sirolimus (SIR, e.g. CypherTM, Cordis) or the
cytostatic paclitaxel (e.g. TaxusTM, Boston Scientiﬁc) from
a permanent polymeric coating. However, despite their
high efﬁcacy regarding the inhibition of ISR, the ﬁrst
generation came under scrutiny, in particular when late
thrombosis and delayed healing were identiﬁed as potential
risks associated with DES [1–3]. As this was on one side
dedicated to the anti-proliferative effect of both drugs on
endothelial cells (EC) in addition to the targeted smooth
muscle cells (SMC) [4] and on the other side to local
hypersensitivity with regard to the permanent polymeric
coating [5], new drugs and biodegradable polymers have
been recently introduced. Commonly used polymers are
nowadays polylactides (PLA) [6, 7] and copolymers, such
as poly(lactide-co-glycolide) (PLGA) [8], while innovative
drugs are often SIR analogues including zotarolimus
[9–11], everolimus [12, 13] and biolimus A9 [14]. More-
over, in order to simultaneously inhibit ISR as a result of
disproportionally increased smooth muscle cell migration
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as well as thrombosis due to failed or incomplete endo-
thelialization, drug combinations such as SIR-heparin,
zotarolimus-dexamethasone, SIR-17b-estradiol and SIR-
genistein are currently under investigation [15]. An
experimental approach in this context was published by
Huang et al. in 2010 who reported the development of a
dual drug-eluting stent (DDES) with SIR and the anti-
thrombotic drug triﬂusal embedded in a biodegradable
PLGA coating [16]. The in vitro results demonstrated that
the developed 2-layered dual-drug coated stents cause a
sustained release of both drugs in rates which effectively
reduce thrombosis and proliferation within the same time
frame. The migration of SMC and re-endothelialization are
however locally focussed processes. While SMC originate
from the vessel, the endothelial layer might be built up by
endothelial progenitor cells circulating within the blood
stream [17, 18]. Novel DES concepts hence foresee an
abluminal location of anti-proliferative drugs in order to
ensure more targeted tissue release and reduced systemic
exposure. Among these, the BioMatrix DES (Biosensors)
with its asymmetric and abluminal PLA coating elutes bi-
olimus A9 into the vessel wall [14]. A similar drug-poly-
mer combination only on the abluminal stent surface is
used in coronary Nobori DES (Terumo Europe MV [19]).
In the present study, we combined both approaches in a
DDES concept, allowing an abluminally focused release of
SIR and a luminally focused release of atorvastatin
(ATOR) from biodegradable poly(L-lactide) (PLLA) stent
coatings. ATOR has been chosen as additive drug as
clinical data suggest a positive impact of statins on the
clinical outcome of patients treated with DES. For instance,
Wang et al. [20] demonstrated in minipigs that treatment
with orally administered ATOR prior to stenting with SIR-
eluting stents led to enhanced re-endothelialization and
neointimal coverage compared to BMS and SIR-eluting
stents without ATOR pretreatment. Next to preclinical
studies, a prospective cohort study from Eindhoven et al.
[21] showed that patients undergoing percutane coronary
intervention treated with ATOR had a lower mortality rate
than using simvastatin. While little is known about the
mechanisms involved in these observations, the stabilizing
effect on atherosclerotic deposits [22] and stimulating
impact on endothelial function [23] are assumed promising
properties for the application of ATOR in the developed
DDES allowing higher local concentrations at the injury
site than by systemic administration.
In this context, we report on the in vitro characterization
of DDES with locally focused SIR and ATOR release
including effects on SMC and EC proliferation and via-
bility, morphology, coating thickness and distribution as
well as in vitro release of SIR and ATOR. The impacts of
processing conditions (tempering, sterilization) and layer
composition are thoroughly discussed making use of a
semi-empirical model introduced by Gallagher et al. [24],
giving insights into the mechanisms behind drug release
and the stent design requirements.
2 Materials and methods
2.1 Materials
All chemicals were purchased from Sigma-Aldrich (Tauf-
kirchen, Germany), Mallinckrodt Baker (Griesheim, Ger-
many), SERVA Feinbiochemica (Heidelberg, Germany),
Thermo Scientiﬁc (Karlsruhe, Germany) or Merck (Darms-
tadt, Germany) in p. a. quality or higher if not indicated dif-
ferently. ATORwas obtained from Pﬁzer Pharma (Karlsruhe,
Germany), and SIR from Sigma-Aldrich (Taufkirchen, Ger-
many) for in vitro cell culture experiments and stent coating.
PLLA (Resomer L210, Mw = 310,000 g/mol, Boehringer
Ingelheim, Ingelheim, Germany) was used as polymeric
coating for coronary cobalt-chromium (CoCr) stents of 3 mm
in diameter and 13 mm in length with a complete surface area
of 57 mm2. Stents and 3 mm 9 15 mm balloon catheter for
stent dilatation were kindly provided by Biotronik SE & Co.
KG (Erlangen, Germany).
2.2 Cell assays
2.2.1 Cell culture
HCASMC and HCAEC of different cell donors were
obtained from PromoCell GmbH (Heidelberg, Germany)
and maintained in culture using optimized culture media
namely smooth muscle cell growth medium 2 and endo-
thelial cell growth medium MV, respectively. The media
with supplements were purchased from PromoCell GmbH
(Heidelberg, Germany). For analysis of proliferation,
HCASMC and HCAEC were seeded at a density of
5 9 103 cells/well in 96-well plates and incubated in the
respective growth medium for 24 h. Subsequently, the cells
were treated for 24 h with basal medium supplemented
with reduced concentrations of FCS (0.5 % for HCAEC
and 0.05 % for HCASMC). Afterwards the cells were
treated for 48 h at 37 C with ATOR (0.1–100 lM) and/or
SIR (1 pM–100 nM) in presence of the respective growth
media. Cell culture was performed at 37 C, with 5 % CO2
in a humidiﬁed atmosphere.
2.2.2 H&E staining
For haematoxylin and eosin staining HCASMC were see-
ded on cover slips at a density of 3 9 105 cells/well in
12-well plates. After treatment with ATOR (1 lM) and/or
SIR (1 lM) cells were ﬁxed with methanol:acetone
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(1:1, v:v) prior to H&E staining. Brieﬂy, cells were incu-
bated with haematoxylin (Merck KGaA, Karlsruhe, Germany),
rinsed with tap water and incubated in eosin solution
(Merck KGaA). After dehydration in ascending ethanol
concentrations, the cover slips were mounted on slides
using Roti Histokitt (Carl ROTH GmbH & Co. KG
Karlsruhe, Germany). Staining was visualized using the
Axio Observer.D1 microscope (Carl Zeiss Jena GmbH,
Jena, Germany).
2.2.3 Cell viability assay
Cell viability was assessed using the commercially avail-
able Fluorometric Cell Viability Kit I (PromoKine GmbH,
Heidelberg, Germany) as described by the manufacturer. In
brief, after treatment the cells were exposed to fresh
medium containing 10 % resazurin. After incubation for
3 h at 37 C and 5 % CO2, ﬂuorescence of resoruﬁn was
determined using a microplate reader (Inﬁnite M200,
Tecan Deutschland GmbH, Crailsheim, Germany) at an
excitation wavelength of 530 nm and an emission wave-
length of 590 nm. Data are expressed as percentage of
control cells treated with the solvent (DMSO) only.
2.2.4 Cell proliferation assay
Cellular proliferation was determined using the commer-
cially available BrdU Cell Proliferation Kit (Roche, Basel,
Switzerland). After 24 h treatment the BrdU labelling
solution was added to the medium followed by 24 h
incubation at 37 C. Subsequently, BrdU incorporation was
measured by ELISA according to the manufacturer’s
instructions. Cells treated with the solvent (DMSO) served
as reference; data are expressed as percent of control. IC50
values were determined calculating sigmoidal dose
response curves using the GraphPad Prism software
(LaJolla, CA, USA).
2.3 Sample preparation
2.3.1 Stent processing
PLLAwas dissolved in chloroform to yield a concentration of
2.5 mg/mL. SIR for abluminal andATOR for luminal coating
were mixed into the polymer solution to obtain a ﬁnal drug
concentration of 17.5 % in PLLA (w/w). The polymer drug
solutionwas then applied to themetallic stent surface via three
different self-developed spray coating processes based on
2-component jet atomization technology: complete, selective
abluminal and selective luminal coating. For complete and
selective abluminal coating, stents were inserted into a holder
of an electropneumatic spray coating system, which applied a
homogeneous coating from the outside by continuous stent
rotation along their longitudinal axis. During selective ablu-
minal coating an additional longitudinal air stream inside the
tubular stent structure was applied in order to selectively
deposit the coating solution on the outer stent surface. In
contrast, selective luminal coatingwas achievedbygeneration
of an outward radial spray inside the tubular stent structure
according to our own patent application [25]. In order to allow
for homogenous coating the stent is translated along its lon-
gitudinal axis. ForDDES, the selective abluminal and luminal
coating with SIR and ATOR respectively were performed
successively in both orders. Intermediate weighing using a
microbalance (UMX5, Mettler Toledo, Giessen, Germany)
during all processes allowed for the adjustment of coating
mass. While 240 ± 20 lg polymeric coating were deposited
on DDES during each process, DES with complete coating
received 460 ± 20 lg coating mass in total. Hence, DDES
and DES received a total SIR load of 1.4 lg/mm2 in accor-
dance to the SIR-eluting stent Orsiro (Biotronik, Berlin,
Germany), which evidenced excellent late luminal loss results
in aﬁrst-in-manexperience in treatment of patientswith single
de novo coronary artery lesions [26]. A deﬁned coating sur-
plus was applied during both DDES coating processes to
achieve a form ﬁt of the coating, implicating additional
deposition of coating mass on the respective opposite stent
surface. If not indicated differently, coated stents were tem-
pered in vacuum for 13.5 h at 80 C after each spraying
process, and terminally sterilizedbya commonethylene oxide
sterilization process.
2.3.2 PLLA ﬁlm preparation
The polymer ﬁlms for thermal and molecular weight
analysis were prepared using the following procedure: 1 g
PLLA was dissolved in 25 mL chloroform and poured into
a glass petri dish (Ø = 9 cm). The chloroform was allowed
to evaporate until a 100 lm thick ﬁlm, as measured by
means of a thickness gauge (2109 Mitutoyo, Mitutoyo
Europe GmbH, Neuss, Germany), had formed. For further
experiments PLLA samples of 5 mm in diameter were
prepared and if indicated tempered at 40 or 80 C and/or
sterilized following the same protocol as during stent
processing.
2.4 In vitro characterization
2.4.1 Electron microscopy
The surface morphology of tempered and sterilized poly-
meric stent coating was assessed by means of a Philips XL
30 ESEM (Philips Electron Optics, Eindhoven, Nether-
lands) operating in the ESEM mode. For analysis of the
structural integrity after expansion, stents were mounted on
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3 mm 9 15 mm balloon catheter and then dilated to their
nominal diameter with 8 bar.
2.4.2 Coating thickness
Determination of coating thicknesses and distribution with
regard to side-selectivity of the process was performed
with stents which have only received either luminal or
abluminal coating. N = 3 stents per subgroup were
embedded in an epoxy resin (EpoThin, Buehler GmbH,
Du¨sseldorf, Germany) and cured for 8 h. Then the samples
were ground in their longitudinal axis and further polished
with an aluminium oxide suspension (Buehler GmbH). The
luminal and abluminal thicknesses of all appearing struts
within the longitudinal cross section were determined at 5
positions by means of optical microscopy (Olympus LEXT
OLS 3000, Hamburg, Germany) using the objective Plan-
Achromat MPlanApo 100 9 NA 0.95 (Olympus). The
mean layer thickness is determined by averaging all single
measurements of each strut and stent. The conﬁdence limit
for a conﬁdence level of 95 % is given as statistical error.
2.4.3 Thermal analysis
Differential scanning calorimetry (DSC)was used to analyze
the crystallinity of PLLA ﬁlms at different processing stages
(tempering and sterilization). The scans of n = 5 PLLA
ﬁlms per subgroup were made on a Mettler-Toledo Ther-
mosystem FP900 (Mettler-Toledo, Schwerzenbach, Swit-
zerland) operating at ambient atmospheric pressure. The
specimens were heated from 45 to 225 C at 5 K/min. The
sample weight was in the range of 2–4 mg. The degree of
crystallinity was calculated using the speciﬁc heat of fusion
in relation to the reference value for totally crystalline PLLA
of 93.7 J/g [27].
2.4.4 Molecular weight analysis
The molecular weight data of PLLA ﬁlms at different
processing stages (tempering and sterilization) was
obtained at 30 C using a PSS SECcurity SEC system
(Polymer Standard Services GmbH, Mainz, Germany)
including a RI detector combined with a WGE Dr. Bures g
2010 viscosity detector (WGE Dr. Bures GmbH, Dallgow,
Germany). Separation was performed with three PSS SDV
columns (103, 105 and 106 A˚ respectively). Chloroform
stabilized with ethanol was used as the eluent at a ﬂow rate
of 1 mL/min. The samples were prepared with a concen-
tration of 1.5 mg/mL in chloroform with hexylbenzene as
internal standard and the injection volume was 0.1 mL.
The molecular weights were calculated by the universal
calibration method using twelve polystyrene calibration
standards in a range between 376 and 2,570,000 g/mol.
2.4.5 Drug recovery
Recovery of SIR and ATOR was evaluated after tempering
and sterilization as well as after completion of the drug
release studies. Therefore, stents were extracted two times,
ﬁrst in 10 and then in 4 mL methanol for 30 and 60 min at
23 ± 2 C respectively. 20 lL of each aliquot were injected
into an Eurospher 100 C18 column, 120 mm 9 4 mm ID
(Wissenschaftlicher Gera¨tebau Dr.-Ing. Herbert Knauer
GmbH, Berlin, Germany). The chromatographic conditions
were: column temperature 50 C; isocratic eluent acetoni-
trile /water 65/35 (v/v); ﬂow rate 1.0 mL/min and UV
detection at 278 nm (SIR) or 248 nm (ATOR) with cali-
brated measurement range 0.1–10.0 mg/L. Both drugs could
be analyzed simultaneously by one HPLC-method. Values
are expressed as fraction of the total drug load as determined
by weighing (fr or frr for recovered fraction and recovered
fraction after drug release respectively).
2.5 Drug release
The time course of SIR and ATOR release was determined
at 23 ± 2 C in 0.9 wt% NaCl supplemented with
0.05 wt% Brij 35 and 0.003 wt% butylated hydroxytoluene
(BHT), which assured SIR and ATOR stability over a time
period of in minimum 4 days as determined in preliminary
experiments (data not shown). Individual stents (n C 3 in
each subgroup) were expanded as described above and
subsequently immersed in 2 mL elution medium for a total
duration of at least 1,000 h. The elution medium was
renewed at periodic intervals in order to realize sink con-
ditions and avoid a saturation of the medium with drugs.
The drug amount released at each time period was deter-
mined by HPLC, applying conditions described above,
after 1:1 dilution with methanol. Remaining drug content
after the drug release studies was evaluated by extraction of
stents as described in the section Drug recovery. Repre-
sented drug release proﬁles result from the accumulation of
the measured values per sampling time and are expressed
as fraction of the total drug load as determined by weigh-
ing. Drug release proﬁles were approximated by Eq. (1),
introduced by Gallagher et al. [24], which combines an
initial fast or burst release phase following ﬁrst-order
kinetics and a subsequent slower release phase.
ft ¼ f1  1 ek1t
 þ ftot  f1ð Þ  ek2tk2t2 max
1þ ek2tk2t2 max
 
ð1Þ
ft is the fraction of drug released at time t, f1the fraction of
drug released during the ﬁrst release phase (burst release),
ftot the maximal fraction of drug released during the whole
process, k1 the ﬁrst order kinetic constant (h
-1) for the ﬁrst
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release phase and k2 the kinetic constant (h
-1) for the
second release phase. tmax has not been discussed within
this study. For the sake of completeness it should be
mentioned that it stands for the time needed to maximal
drug release rate within the second release phase. t1, which
has been recalculated by the ﬁtted equation, presents the
time when f1 is reached. Origin 8.1G was used for data
ﬁtting.
2.5.1 Statistics
If not indicated differently, mean values and standard
deviations (SD) were analyzed using IBM SPSS software
20.0. Conﬁdence intervals (CI) and data of cell assays were
analyzed using Student0s t test with p\ 0.05 being deﬁned
as signiﬁcantly different. IC50 values were determined
calculating sigmoidal dose response curves using the
GraphPad Prism software (LaJolla, CA, USA).
3 Results and discussion
3.1 Applicability of the combination of ATOR and SIR
in DDES
The developed DDES foresee the inhibition of ISR without
provoking long-term impact on healing and re-endotheli-
alization, by a preferential abluminal location of SIR and a
luminal location of ATOR within a biodegradable PLLA
coating. Hereby we aim at the combination of the highly
potent anti-proliferative effect of SIR on SMC and reduced
impact on EC via minimized systemic exposure of SIR
with the general observed positive effects of ATOR as the
stabilization of atherosclerotic deposits [22] and the stim-
ulation of endothelial function on the clinical outcome of
patients treated with DES [23]. However, this combination
on DDES does only become applicable when ATOR does
not annihilate the anti-proliferative effect of SIR on SMC if
both drugs accumulate in the vessel wall or does itself
provoke signiﬁcant anti-proliferative effects on EC in high
local concentrations as reached by DES. In this context, we
investigated the inﬂuence of both substances on prolifera-
tion and viability of HCASMC and HCAEC separately and
in co-treatment.
3.1.1 Inﬂuence of ATOR and SIR on proliferation
and viability of HCASMC und HCAEC
In order to assess the impact of ATOR and SIR on
HCASMC and HCAEC proliferation a BrdU ELISA was
performed revealing signiﬁcant anti-proliferative effects of
both substances on HCASMC. As shown in Fig. 1a, b,
ATOR inhibited HCASMC proliferation with an IC50 value
of 0.77 lM [Conﬁdence Interval (CI) 0.49–1.21 lM],
while incubation with SIR supported the previously
reported anti-proliferative potency of this clinically used
compound with an IC50 value of 0.41 nM [CI 0.19–0.88]
[28, 29].
While in accordance to literature the inhibitory capacity
of SIR in HCAEC (IC50 value of 0.15 nM, CI 0.08–0.29)
exerted a similar value to that measured in HCASMC [28],
the observed IC50 value of ATOR (4.1 lM, CI 3.3–5.2)
was threefold higher for HCAEC compared to HCASMC
(data not shown). The observed anti-proliferative effect of
SIR on HCAEC is hence about four magnitudes higher
than that measured for ATOR, which lets assume that re-
endothelialization will be less impaired by DDES releasing
ATOR preferentially to the lumen and SIR preferentially to
the vessel wall than by commercial SIR-eluting stents.
Interestingly, both substances revealed no signiﬁcant
cytotoxic effects compared to DMSO treated cells within
the examined concentration range, as measured by the
described resazurin-based cell viability assay (data not
shown).
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Fig. 1 Anti-proliferative effects of atorvastatin (ATOR) and siroli-
mus (SIR) on human coronary artery smooth muscle cells
(HCASMC). HCASMC were treated with a ATOR and b SIR for
48 h, respectively. Proliferation was measured by incorporation of
BrdU. Data are represented as mean ± SD; n = 3. IC50 values,
determined by calculation of sigmoidal dose response curves, and the
95 % conﬁdence interval (CI) are indicated
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3.1.2 Co-treatment with ATOR and SIR
In order to guarantee the maintenance of the anti-prolif-
erative effect of SIR on HCASMC in developed DDES,
HCASMC of one donor, which showed high effect to SIR
incubation in previous experiments, were treated with SIR
(10 nM) in the presence or absence of ATOR (1 lM). As
shown in Fig. 2a co-administration of ATOR reduced the
anti-proliferative efﬁcacy of SIR only slightly to
28.6 ± 2.26 %; mean % of control ± SD. In order to
furthermore obtain insight into morphological changes
induced by ATOR or SIR, treated cells were stained with
haematoxylin and eosin. Surprisingly, even if signiﬁcantly
reduced cellular proliferation was detected performing the
sensitive BrdU ELISA no impact on cell density or mor-
phology was observed in the presence of 10 nM SIR
(Fig. 2b). In subsequent experiments a higher concentra-
tion of SIR (1 lM) was used. As shown in Fig. 2b, H&E
staining revealed lower density of the cells in the presence
of SIR. Additionally, treatment with 1 lM ATOR signiﬁ-
cantly reduced cell density (Fig. S1 in Supplementary
material). In the presence of both substances, SMC
appeared expanded. This morphological change might be
explained by the reduced cell count.
3.2 Coating morphology and distribution of DDES
Several different technological approaches are currently
being applied for the coating of DES. While some of them
are already used for commercial products, others are still
under development. Most widely used are probably dip-
coating and 2-component jet or ultrasonic atomization
processes. Selective coating of either the abluminal or
luminal surface of the stent, however, requires adapted or
novel technologies. For example, selective abluminal
coating of the Biomatrix stent has been achieved via an
advanced spray coating technology, equipped with an
imaging system, which allows for exact determination of
the stent skeletal elements and deﬁnes the traverse path of a
coating dispenser head [30]. In this way, the abluminal
surface of stent struts can be coated selectively. Moreover,
a technique for selective luminal stent coating was pro-
posed by masking the outer stent surface with a sleeve and
subsequent insertion of a spraying nozzle inside the stent
[31]. However, both processes will potentially lead to
coatings with sharp edges, which could result in coating
delamination during stent implantation. The here presented
spray coating processes provide form-ﬁt of the polymer
coatings around the entire cross section of the individual
stent struts. Representative stent strut cross sections are
shown in Table 1. By reason of the coating set-up, the
luminal coating process allows high selectivity with about
10 % of the drug/polymer solution being deposited at the
abluminal stent surface. In contrast, the abluminal process
is less selective with up to 30 % of the drug/polymer
solution being deposited on the luminal stent surface.
However, in comparison to the conventional complete
spray coating process, which results in average in a coating
distribution of 60 % abluminal and 40 % luminal (data not
shown), selectivity of the abluminal stent coating was
enhanced by the novel process. For production of DDES,
the two selective coating processes were combined in both
orders. In either case, a smooth and uniform surface
without any layer boundaries due to the two-step coating
process was observed, as exemplarily shown for DDES,
obtained by a luminal/abluminal coating sequence
(Fig. 3a–c). Furthermore, it was observed that structural
integrity of the coating was maintained after steriliza-
tion, crimping and full expansion of DDES prototypes
(Fig. 3d–f).
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Fig. 2 Inﬂuence of atorvastatin (ATOR) in combination with sirol-
imus (SIR) on proliferation and viability of human coronary artery
smooth muscle cells (HCASMC). HCASMC were treated with ATOR
in the presence or absence of SIR. (a) Proliferation of HCASMC after
48 h incubation with SIR (10 nM) and ATOR (1 lM) was measured
by incorporation of BrdU. Data are represented as mean ? SD,
n = 3. (b) H&E staining of HCASMC after 48 h incubation with
ATOR (1 lM) in presence or absence of SIR (10 nM)
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3.3 Drug recovery and in vitro drug release of DDES
3.3.1 Impact of tempering and sterilization
The tempering and sterilization procedures, which have
been chosen due to their applicability for PLLA, as evi-
denced by absence of solvent (chloroform) and molecular
weight maintenance [32], were evaluated in detail with
regard to SIR and ATOR stability at the example of DDES,
obtained by a luminal–abluminal coating sequence. Per-
formed HPLC analysis of the total content of stents after
the different processing steps fortunately revealed in each
case more than 97 % of the theoretically calculated total
drug load as estimated by the observed coating masses.
Table 1 Coating distributions of the site-selective spray coating
processes. Optical microscopy images of one representative strut
cross section of stents containing 250 lg drug/PLLA coating either
applied via the abluminal- or the luminal-selective spraying process
with indicated measuring positions and measured coating thicknesses
Abluminal coating Luminal coating
Optical microscopy image of one representative strut
Measuring position abluminal 1 2 3 4 5 Mean 1 2 3 4 5 Mean
Coating thickness (lm) 4.46 4.95 5.19 4.93 3.92 4.69 0.77 0.51 0.76 0.89 1.52 0.38
Measuring position luminal 6 7 8 9 10 Mean 6 7 8 9 10 Mean
Coating thickness (lm) 1.01 1.26 1.64 1.02 3.55 1.70 5.22 5.69 6.20 6.45 6.73 6.06
Average abluminal coating thickness over all appearing
struts of 3 stents (lm) (±conﬁdence limit, conﬁdence
level 95 %)
4.60 ± 0.16 0.69 ± 0.06
Average luminal coating thickness over all appearing
struts of 3 stents (lm) (±conﬁdence limit, conﬁdence
level 95 %)
1.93 ± 0.09 5.78 ± 0.28
Fig. 3 Representative electron micrographs of at 80 C tempered DDES, obtained by a luminal–abluminal coating sequence, (a–c) prior and
(d–f) after sterilization, crimping and expansion to their nominal diameter with 8 bar by means of conventional balloon catheter
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Consequently, SIR- and ATOR-containing DDES can be
processed using standard conditions, while the tempering
process has been applied twice after each of the two coating
steps in order to allow for precise weighing of the deposited
coating mass. Furthermore, we investigated the impact of
tempering and sterilization on the in vitro drug release, ex-
emplarily depicted in Fig. 4 for SIR of DDES, obtained by a
luminal–abluminal coating sequence. Independently of the
process, a two-phase release proﬁle with an initial burst
release phase following ﬁrst-order kinetics and a subsequent
slower release phase, which could be well ﬁtted by Eq. (1)
with r2[ 0.95, was observed. Estimated parameters
obtained by approximation are shown in Table 2. Striking is
the difference in total SIR fraction released, which is more
than doubled for sterilized DDES, tempered at 40 C and
even decupled for DDES tempered at 80 C independently
of sterilization in comparison to unsterileDDES, tempered at
40 C. The tendency is the same for ATOR release (Fig. S2
in Supplementary material). It is well known that drug
release rate from polymers is generally accelerated by less
crystallinity and lower molecular weight [33]. In this con-
text, we prepared sterile and unsterile PLLA ﬁlms, which
have been tempered at 40 or 80 C in order to investigate
possible changes in crystallinity or molecular weight. While
no considerable differences are observed in molecular
weight and the degree of crystallinity (Table 3), DSC-curves
revealed the complete disappearance of the glass transition
for sterilized and non-sterilized PLLA ﬁlms, tempered at
80 C (Fig. S3 in Supplementarymaterial). At ﬁrst sight, this
might seem contradictory, but it has been previously reported
that tempering of semi-crystalline polymersmight lead to the
densiﬁcation of the amorphous phase and the increase of a
so-called rigid amorphous fraction without change in the
crystalline fraction [34, 35]. Also contradictory appears the
enormous increase in release rate with smaller mobile
amorphous fraction (as the conventional amorphous phase
might be called). In accordance to Hurrell et al. [36], who
reported on the release of theophylline from polyglycolide,
we assume two factors which could account for the higher
release from DDES tempered at 80 C. First, a non-linear
drug distribution through the sample may be formed during
the temper process by drug diffusion and partition towards
the surface. The second factor which may contribute to
enhanced burst drug release is an increased content of drug in
the mobile amorphous phase of the polymer due to the
exclusion of drug molecules from crystalline and rigid
amorphous phases created during tempering. Both mecha-
nisms would lead to drug supersaturation in conﬁned regions
and hence drug crystallization. If then water enters the
sample, these drug crystals dissolve, causing the polymeric
matrix to be more porous and drugs are released more
quickly compared to samples with more homogeneous drug
distribution. Additionally, remaining solvent in coatings
tempered at 40 C might reduce the water interpenetration
within the bulk material leading to a further deceleration of
drug release.
In summary, this discussion clearly highlights the
importance of tempering stent coatings, not only for
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Fig. 4 Sirolimus (SIR) release proﬁles of non-sterilized and sterilized
DDES (obtained by a luminal–abluminal coating sequence and
tempered at 40 or 80 C) at 23 ± 2 C in 0.9 wt% NaCl supple-
mented with 0.05 wt% Brij 35 and 0.0003 wt% BHT. Each curve
represents 3 stents (mean values ± SD), ﬁtting was performed using
Eq. (1)
Table 2 Estimated kinetic parameters obtained by approximation
using Eq. (1) combining an initial fast phase and a subsequent slower
release phase for sirolimus (SIR) release proﬁles of non-sterilized and
sterilized DDES (obtained by a luminal–abluminal coating sequence
and tempered at 40 or 80 C) at 23 ± 2 C in 0.9 wt% NaCl
supplemented with 0.05 wt% Brij 35 and 0.0003 wt% BHT
Processing f1 (-) k1 (h
-1) t1 (h) ftot (-) k2 (h
-1) r2 (-) frr (-)
40 C tempering no sterilization 0.03 ± 0.00 0.10 ± 0.02 13 0.06 ± 0.00 0.01 ± 0.00 0.9834 0.93 ± 0.01
40 C tempering EO-sterilization 0.06 ± 0.01 0.55 ± 0.18 2 0.14 ± 0.00 0.01 ± 0.00 0.9583 0.81 ± 0.09
80 C tempering no sterilization 0.34 ± 0.02 0.36 ± 0.06 5 0.58 ± 0.01 0.02 ± 0.00 0.9853 0.81 ± 0.01
80 C tempering EO-sterilization 0.36 ± 0.02 0.23 ± 0.03 9 0.59 ± 0.01 0.02 ± 0.00 0.9907 0.77 ± 0.02
f1 drug fraction released during the burst release, k1 kinetic constant of the burst release, t1 time to reach f1, ftot total drug released during process,
k2 kinetic constant of the second release phase, r
2 coefﬁcient of determination for ﬁtting Eq. (1), frr recovered drug fraction after completed drug
release study (1,000 h), Fractions are calculated in relation to the theoretical drug amount
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complete solvent removal but also for the achievement of
adequate and sustained drug release.
3.3.2 Impact of DDES design
Besides the stent processing, drug release is also likely
inﬂuenced by the coating design. In this context, we
examined the in vitro drug release of various DDES and
DES designs with regard to release proﬁles of SIR and
ATOR. Corresponding drug release proﬁles are shown in
Fig. 5 and estimated kinetic parameters obtained by
approximation using Eq. (1) in Table 4.
As the here applied spraying processes provide form-ﬁt
polymer coatings at the abluminal and luminal side, the order
of their combination will lead to a capping of either the SIR-
or the ATOR-containing layer (Table 1). In detail, the SIR-
containing coating of DDES prototypes, obtained by an
abluminal–luminal coating sequence, is covered by a 1 lm
and a 6 lm thick polymeric coating at the outer or the inner
surface respectively. In other words, intended SIR eluting
from the abluminal side has to pass a small diffusion barrier
of 1 lm,while unwanted SIR elution from the luminal side is
shielded by a 6 lm thick polymeric layer. Compared to
DDES prototypes, obtained by a luminal–abluminal coating
sequence, such that SIR elutes without diffusion barrier, a
decreased drug release rate of the burst release phase k1 is
observed (luminal–abluminal coating: 0.23 h-1, abluminal–
luminal coating: 0.08 h-1, Table 4). However, the rates
Table 3 Molecular weight (Mw) and degree of crystallinity of non-
sterilized and sterilized PLLA ﬁlms tempered at 40 C or 80 C
Processing Mw (g/mol) Degree of
crystallinity (%)
40 C tempering no
sterilization
317,000 ± 3,000 31 ± 2
40 C tempering
EO-sterilization
318,000 ± 6,000 31 ± 3
80 C tempering
no sterilization
319,000 ± 5,000 32 ± 2
80 C tempering
EO-sterilization
316,000 ± 9,000 33 ± 5
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luminal
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Fig. 5 Sirolimus (SIR) and atorvastatin (ATOR) release proﬁles of
sterilized and at 80 C tempered DDES and DES prototypes at
23 ± 2 C in 0.9 wt% NaCl supplemented with 0.05 wt% Brij 35 and
0.0003 wt% BHT. (a) SIR and ATOR release proﬁle of DDES
obtained by a abluminal–luminal coating sequence, (b) SIR and
ATOR release proﬁle of DDES obtained by a luminal–abluminal
coating sequence, (c) SIR release proﬁles of DES obtained by a
complete SIR-containing coating with optional ATOR-containing
topcoat for simulation of the luminal coating of DDES obtained by an
abluminal–luminal coating sequence. (d) SIR release proﬁle of DES
obtained by a complete SIR-containing coating. Each curve represents
3 stents (mean values ± SD), ﬁtting was performed using Eq. (1)
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result from the combination of both, drug release from the
inner and the outer surface, raising the question whether
unwanted SIR elution rate from the luminal side of DDES
obtained by an abluminal–luminal coating sequence is efﬁ-
ciently reduced, while maintaining an effective SIR release
at the abluminal side. In order to solve this question we
simulated the luminal coating of a DDES, obtained by an
abluminal–luminal coating sequence. According to Table 1
the luminal coating of this DDES is build up by a 2 lm thick
SIR-containing basecoat and an ATOR-containing topcoat
of 6 lm in thickness. As this correlates to 30 % of the ﬁrst
and 90 % of the second coating having both a total mass of
250 lg for each stent side, we generated a DDESwith a SIR-
containing basecoat of 150 lg and an ATOR-containing
topcoat of 450 lg via the complete spraying process,
detailed in the experimental section. In vitro release studies
in comparison to DES, containing only the SIR-containing
basecoat, demonstrate a decrease of the burst release rate
constant k1 from 1.59 to 0.02 h
-1 (Table 4; Fig. 5c). This
indicates on one hand an effective shielding of the luminal
SIR elution and also suggests that the abluminal SIR elution
of DDES, obtained by an abluminal–luminal coating
sequence, is not considerably inﬂuenced. The in vitro release
proﬁle of DES with a complete 480 lg SIR-containing
coating, evidencing similar drug fraction released during
burst phase and in total as well as release rate constants as
DDES obtained by an abluminal–luminal coating sequence
(Table 4; Fig. 5d), supports this hypothesis.
The total fraction of released ATOR is for both DDES
prototypes higher than for SIR (Figure 5a, b), which might
be dedicated in accordance to Pan et al. [37] to its lower
molar mass (ATOR 558.65 g/mol, SIR 914.17 g/mol)
resulting in higher diffusion coefﬁcient at similar solubility
in aqueous media. Its abluminal elution and accumulation in
the vessel wall, which is in particular expected for DDES,
obtained by an abluminal–luminal coating sequence, is not
considered to reduce the DDES performance, as in vitro cell
assays evidenced the maintenance of the potent anti-prolif-
erative effect of SIR in the presence of ATOR.
Summarizing these in vitro data, the coating sequence
for DDES should be rather abluminal–luminal than lumi-
nal–abluminal. The achieved reduction of the amount of
SIR eluted luminally could then potentially minimize the
induction of endothelial dysfunction, while efﬁcacy con-
cerning the inhibition of neointima proliferation is assumed
due to the SIR release proﬁle being similar to completely
coated SIR-eluting stents. The luminal–abluminal coating
sequence would in contrast lead to higher local SIR con-
centrations due to the increased release rate in the ﬁrst
release phase, which might in the worst case result in an
even enhanced endothelial dysfunction.
4 Conclusions
Novel DES concepts often either foresee an abluminal
location of anti-proliferative drugs in order to ensure more
targeted release and reduced systemic exposure or the use
of drug combinations for simultaneous inhibition of ISR as
a result of disproportionally increased smooth muscle cell
Table 4 Estimated kinetic parameters obtained by approximation
using Eq. (1) combining an initial fast phase and a subsequent slower
release phase for sirolimus (SIR) and atorvastatin (ATOR) release
proﬁles of sterilized and at 80 C tempered DDES and DES
prototypes at 23 ± 2 C in 0.9 wt% NaCl supplemented with
0.05 wt% Brij 35 and 0.0003 wt% BHT
Drug Layer composition f1 (-) k1 (h
-1) t1 (h) ftot (-) k2 (h
-1) r2 (-) frr (-)
Sirolimus (SIR) 1. SIR abluminal
2. ATOR luminal
0.28 ± 0.02 0.08 ± 0.01 26 0.50 ± 0.01 0.02 ± 0.00 0.9938 0.71 ± 0.01
1.ATOR luminal
2. SIR abluminal
0.36 ± 0.02 0.23 ± 0.03 9 0.59 ± 0.01 0.02 ± 0.00 0.9907 0.77 ± 0.02
Simulated luminal coating
1. SIR
0.33 ± 0.03 1.59 ± 0.27 1 0.52 ± 0.01 0.13 ± 0.04 0.9819 0.81 ± 0.01
Simulated luminal coating
1. SIR
2. ATOR
0.42 ± 0.03 0.02 ± 0.00 116 0.56 ± 0.01 0.01 ± 0.00 0.9976 0.79 ± 0.01
SIR 0.26 ± 0.02 0.10 ± 0.02 14 0.52 ± 0.02 0.01 ± 0.00 0.9789 0.78 ± 0.02
Atorvastatin
(ATOR)
1. SIR abluminal
2. ATOR luminal
0.41 ± 0.02 0.28 ± 0.04 7 0.69 ± 0.01 0.03 ± 0.00 0.9912 0.81 ± 0.02
1. ATOR luminal
2. SIR abluminal
0.29 ± 0.02 0.04 ± 0.01 51 0.64 ± 0.01 0.01 ± 0.00 0.9923 0.82 ± 0.03
f1 drug fraction released during the burst release, k1 kinetic constant of the burst release, t1 time to reach f1, ftot total drug released during process,
k2 kinetic constant of the second release phase, r
2 coefﬁcient of determination for ﬁtting Eq. (1), frr recovered drug fraction after completed drug
release study, fractions are calculated in relation to the theoretical drug amount
2598 J Mater Sci: Mater Med (2013) 24:2589–2600
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proliferation and migration as well as thrombosis due to
failed or incomplete endothelialization. In the present
study, we combined both approaches by the establishment
of an abluminally focused release of the potent anti-pro-
liferative drug SIR and a luminally focused release of
ATOR with stabilizing effect on atherosclerotic deposits
and stimulating impact on endothelial function from bio-
degradable PLLA-based stent coatings. In performed cell
culture assays, we were able to evidence that ATOR does
not annihilate the anti-proliferative effect of SIR on SMC
and provoke any harmful effects on EC at concentrations
below 1 lM. The here applied spraying processes provide
form-ﬁt polymer coatings at the abluminal and luminal side
with 70 and 90 % of the drug/polymer solution being
deposited at the intended stent surface. In either case, a
smooth and uniform surface with structural integrity after
sterilization, crimping and full expansion was observed,
evidencing the good applicability and performance of the
especially adapted spraying process for the generation of
DDES. As stability of both drugs after tempering and
sterilization was demonstrated, SIR and ATOR-containing
DDES can be processed using standard conditions: 80 C
tempering and a common ethylene oxide sterilization
process. In vitro drug release studies revealed for both
drugs a two-phase release proﬁle with an initial burst
release phase following ﬁrst-order kinetics and a sub-
sequent slower release phase, which could be well ﬁtted by
a semi-empirical model introduced by Gallagher et al. [24].
From those data we conclude that tempering of the sprayed
coatings at elevated temperatures is not only important for
complete solvent removal but also for the achievement of
adequate and sustained drug release, a temperature increase
from 40 to 80 C during drying decupled the total drug
fraction released during a deﬁned time period. Importantly,
based on our data from the in vitro release the coating
sequence for DDES should be rather abluminal–luminal
than luminal–abluminal. It might be hypothesized that the
thereby achieved reduction of SIR eluted luminally would
minimize the induction of an endothelial dysfunction,
while exerting similar inhibitory efﬁcacy concerning the
neointimal proliferation due to the similar SIR release
proﬁle as shown for the completely coated SIR-eluting
stents. In summary, in vitro data of the developed DDES
concerning effects on smooth muscle cell and endothelial
cell proliferation and viability, coating morphology, layer
thickness and distribution as well as in vitro release of SIR
and ATOR are promising. Their safety and efﬁcacy also
with regard to healing however warrants further research
using in vivo models.
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Figure S1. Influence of atorvastatin plus sirolimus on morphology of human coronary artery smooth muscle cells (HCASMC). 
HCASMC were treated with atorvastatin (1 µM) in the presence or absence of sirolimus (1 µM) followed by H&E-staining of 
HCASMC after 48hr incubation. 
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Figure S2. Atorvastatin release profiles of unsterile and sterile DDES tempered at 40 °C or 80 °C at 23 ± 2 °C in 0.9% w/w 
NaCl supplemented with 0.05 w% Brij 35 and 0.0003 w% BHT. Each curve represents 3 stents (mean values ± SD). 
Figure S3. Differential scanning calorimetry – curves for unsterile and sterile PLLA (Resomer L210, Boehringer Ingelheim, 
Germany) films tempered at 40 °C (L210, s-L210) or 80 °C (L210-T, s-L210-T). Each curve represents the mean of 5 PLLA 
films.
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ABSTRACT: Enhanced proliferation of human coronary artery smooth
muscle cells (HCASMCs) and thereby formation of neointima is one of
the factors contributing to failure of coronary stents. Even if the use of
drug eluting stents (DES) and thereby the local delivery of cytotoxic
compounds has signiﬁcantly improved the clinical outcome, unselective
cytotoxic eﬀects are assumed to hamper clinical success. Novel
pharmacological approaches are required to enhance cellular selectivity
of locally delivered drugs. Cell speciﬁc overexpression of a drug
transporter could be used to enhance cellular accumulation and therefore
cell speciﬁcity. In the herein reported study we tested the possibility of cell
speciﬁc transporter expression to enhance drug eﬀects in HCASMCs. We
generated adenoviral constructs to overexpress the organic cation
transporter 1 (OCT1) under control of the promoter of SM22α, which
had been previously reported as muscle cell speciﬁc gene. First the activity of the SM22α-promoter was assessed in various cell
types supporting the notion of muscle cell speciﬁcity. Subsequently, the activity of the transporter was compared in infected
HCAECs and HCASMCs revealing enhanced accumulation of substrate drugs in HCASMCs in presence of the SM22α-
promoter. Testing the hypothesis that this kind of targeting might serve as a mechanism for cell-speciﬁc drug eﬀects, we
investigated the impact on paclitaxel treatment in HCASMC and HCAECs, showing signiﬁcantly increased antiproliferative
activity of this substrate drug on muscle cells. Taken together, our ﬁndings suggest that cell-speciﬁc expression of transport
proteins serves as mechanism governing the uptake of cytotoxic compounds for a selective impact on targeted cells.
KEYWORDS: drug delivery, pharmacokinetics, vascular smooth muscle cells, paclitaxel, organic cation transporter1 (OCT1), SM22
■ INTRODUCTION
Drug-eluting stents (DES) have been an outstanding improve-
ment in interventional therapy of coronary atherosclerosis.
Indeed, the ﬁrst generation DES, which were coated with
substances such as the mTOR-antagonist sirolimus (rapamy-
cin) (Cypher, Johnson & Johnson) or the mitotic inhibitor
paclitaxel (Taxus, Boston Scientiﬁc), have been shown to
signiﬁcantly improve clinical outcome of patients after
angioplasty with stent implantation (summarized in ref 1). It
is assumed that one of the mechanisms involved in this
improvement is the reduction of neointima formation due to
the antiproliferative drugs. The histopathological correlate of
neointima formation is the proliferative activation of vascular
smooth muscle cells, which is signiﬁcantly reduced in the
presence of sirolimus and paclitaxel.2 However, even if
neointima formation is decreased, there is still the issue of
delayed arterial healing, characterized by incomplete stent strut
endothelialization in presence of cytotoxic compounds. Delayed
arterial healing is assumed to contribute to the occurrence of in-
stent thrombosis.3
In accordance, it is aim of the ﬁeld to identify agents with
cell-speciﬁc eﬃcacy. The perfect drug should enhance re-
endothelialization of the stent struts, while inhibiting
proliferation and migration of smooth muscle cells.1 From a
pharmacological point of view, there are two diﬀerent
approaches to realize cell-speciﬁc eﬀects of drugs: the ﬁrst
would be to identify cell-speciﬁc drug targets; the second would
be to improve pharmacokinetics of candidate drugs. The latter
concept is the subject of the herein reported study. One of the
mechanisms contributing to pharmacokinetics of xenobiotics is
the expression of drug transporters, which facilitate trans-
membrane movement of substrates.4 The ﬁrst transporters
identiﬁed were members of the ATP-binding cassette super-
family mediating ATP-dependent cellular eﬄux of their
substrates. In accordance, overexpression of those transporters
has been associated with the incidence of multidrug resistance
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in cancer cells.5 Especially P-glycoprotein (P-gp, MDR1,
ABCB1) has been focus of several studies, aiming to inhibit
transport activity to overcome chemoresistance.6 However,
MDR1 is also expressed in non-malignant transformed tissues,
taking part in the elimination and distribution of its substrates
in the organism, thereby hampering the success of transporter
inhibition to improve cancer treatment.7 With the identiﬁcation
of drug transporters facilitating cellular uptake the concept of
renal or hepatic elimination of drugs has changed. Indeed,
nowadays we know that members of the solute carrier (SLC)
protein superfamily are mediating cellular entry of a variety of
compounds prior to metabolism and/or eﬄux, thereby
representing one mechanism limiting hepatic or renal
elimination.8
Organic cation transporters (OCT) are one subfamily within
the superfamily of SLC transporters, mediating sodium
independent uptake of exogenous and endogenous cations.9
In this study we used the hepatic uptake transporter OCT1
(SLC22A1),10 which has been shown to transport a variety of
drugs, including the clinically established DES-drug paclitaxel.11
To drive speciﬁc expression of the drug transporter in the
targeted cells the promoter of transgelin (SM22α) a commonly
used marker of smooth muscle cells was used. This promoter
has been previously reported as a mechanistic tool to perform
cell type speciﬁc deletion and/or overexpression in mouse
models.12,13
The herein reported data provide evidence that cell-speciﬁc
overexpression of a drug transporter can be used to enhance
cellular accumulation and therefore eﬃcacy of compounds with
intracellular drug targets.
■ EXPERIMENTAL SECTION
Cell Lines. MDCKII (ATCC no. CRL-2936) and A549
(ATCC no. CCL-185) were obtained from ATCC. HL-1 cells
are murine cardiomyocytes and have been previously described
by Claycomb et al.14 Primary isolated human coronary artery
endothelial cells (HCAECs) and human coronary artery
smooth muscle cells (HCASMCs) were purchased from
PromoCell GmbH (Heidelberg, Germany).
Real-Time PCR. For quantiﬁcation of mRNA expression of
SM22α (Transgelin) and the housekeeping gene 18S rRNA
total mRNA was isolated from HCAECs and HCASMCs using
peqGOLD RNAPure as described by the manufacturer. After
quantiﬁcation of mRNA content using the NanoDrop 2000
(peqlab, Erlangen, Germany) cDNA synthesis was performed
using the High Capacity cDNA Reverse Transcription Kit (Life
Technologies, Darmstadt, Germany). A portion of 20 ng of
cDNA was used for real-time PCR using predeveloped
TaqManAssays Hs01038777_g1, and Hs99999901_s1 for
detection of SM22α (transgelin) and 18S rRNA, respectively,
the TaqManGene Expression Master Mix, and the 7900HT
Fast Real-Time PCR System (Life Technologies).
Cloning of the Promoter Region of SM22α. A 1269 bp
fragment of the 5′-UTR of human SM22α was ampliﬁed from
human genomic DNA using the following primers
SM22prom_for 5′-ACGTGGTACCCCCCAAGATCCC-
TGAAGCCAGGTA-3′ and SM22prom_rev 5′-ACGT-
CTCGAGGCCTGCCTGAAATGCACCCACT-3′. The result-
ing PCR product was ﬁrst subcloned into pGL3-basic
(Promega, Mannheim, Germany) where the luciferase coding
region was replaced by eGFP using the restriction enzymes
KpnI and XhoI. After sequencing the insert, SM22-eGFP-polyA
was subcloned into pENTR1A Dual Selection (Life Tech-
nologies), which was then used in an LR Clonase mediated
recombination reaction for transfer into pAd/PL-DEST a
replication deﬁcient variant of human Adenovirus subtype 5
(Life Technologies). After ampliﬁcation in E. coli the isolated
adenoviral vector was digested with PacI and transfected into
HEK293A cells (Life Technologies) using Lipofectamin 2000
(Life Technologies) for virus production. The virus was
isolated and tested for plaque forming units as described in
the manufacturer’s instructions.
eGFP Fluorescence and Immunoﬂuorescent Staining.
Eﬃcacy of infection and expression was determined using
enhanced green ﬂuorescence protein (eGFP) ﬂuorescence.
Twenty-four hours after seeding 2 × 105 cells/well on
coverslips, cells were infected with 50 pfu/cell of the respective
pAD-promoter-eGFP construct. Cytomegalivirus (CMV)-pro-
moter driven expression served as control for the SM22α-
promoter. Forty-eight hours after infection cells were ﬁxed with
4%-paraformaldehyde, washed twice with PBS, and incubated
for 15 min with 4′,6-diamidino-2-phenylindole (DAPI) diluted
1:1000 in PBS for nuclei stain. After that the coverslips were
mounted onto slides and green ﬂuorescence was determined
using the ﬂuorescence microscope Axio Observer D1 (Zeiss
GmbH, Jena, Germany). Immunoﬂuorescent staining was
performed 48 h after adenoviral infection (50 pfu/cell) or 48
h in culture in virus naıv̈e cells, respectively. In detail, after
ﬁxation with methanol−ethanol (1:1), cells were washed twice
with PBS and blocked for 1 h with PBS containing 5% FCS and
0.01% Triton-X 100. Subsequently, the cells were incubated
with the respective antibody, ab123128 (abcam, Cambridge,
UK) for OCT1 diluted 1:25, and ab14106 (abcam) for SM22α
diluted 1:250, at 4 °C overnight in a humidiﬁed atmosphere.
After that, cells were washed several times with PBS and
incubated with a ﬂuorescence labeled secondary antibody
(Alexa Fluor 568 or Alexa Fluor 488, Life Technologies). After
staining with DAPI and mounting on slides, ﬂuorescence was
visualized using the Axio Observer.D1 microscope (Zeiss
GmbH).
HE Staining of Cultured Cells. To determine the
inﬂuence of viral infection on cell morphology, cells were
infected with 50 pfu/cell of the control virus pAD-CMV-lacZ
(Life Technologies). After 48 h of infection cells were ﬁxed
with ice-cold methanol−aceton (1:1) for 15 min. Then
Hematoxylin Eosin staining was performed as follows. First,
cells were incubated with Hematoxylin solution, Gill No. 3 for
15 min. After washing several times with distilled water and
blueing with tap water eosinophilic structures were counter-
stained with an alcoholic eosin solution. Staining was visualized
using the Axio Observer.D1 microscope (Zeiss GmbH).
Transport Assay. The transport activity of OCT1 was
determined 48 h after adenoviral infection with 50 pfu/cell.
Brieﬂy, cells were washed twice with incubation buﬀer (140
mM NaCl, 5 mM KCl, 1 mM KH2PO4, 1.5 mM CaCl2, 5 mM
glucose, and 12.5 mM Hepes, pH 7.3), then radiolabeled
substances [3H]-1-methyl-4-phenylpyridinium ([3H]-MPP+) or
[14C]-Tetraethylammonium bromide ([14C]-TEA) (100 000
dpm/well) were added and incubated for the indicated times.
After incubation cells were washed two times with ice-cold
phosphate buﬀered saline (PBS). Cellular accumulation of the
radiolabel was determined after cell lysis in 400 μL of SDS-
EDTA buﬀer (0.2% SDS, 5 mM EDTA) using a liquid
scintillation counter (type 1409, LKB-Wallac, Turku, Finland).
Western Blot Analysis. For protein analysis cells were
harvested in 5 mM Tris-HCl supplemented with aprotinin (1
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mM), leupeptin (1 mM), and phenylmethylsulfonyl ﬂuoride
(0.1 μM). Afterward the cells were lysed by 5 cycles of freezing
in liquid nitrogen and thawing at 37 °C. The protein content
was determined performing bicinchoninic acid (BCA) assays
(Thermo Fisher Scientiﬁc, Bonn, Germany). In total 25 μg of
the lysate were separated by SDS-PAGE and electro-transferred
to a nitrocellulose membrane using a TANK blotting system
(Bio-Rad, Munich, Germany). After blocking with 5% FCS in a
mixture of Tris-buﬀered saline and 0.05% Tween 20 (TBS-T),
the membranes were incubated with the primary antibody. The
anti-SM22α antibody (ab14106, abcam) was diluted 1:2000,
anti-GFP antibody (Santa Cruz) was diluted 1:2500, the anti-
Actin-antibody (Santa Cruz) was diluted 1:2500, and the
antivascular endothelial (VE) cadherin-antibody (ab33168,
abcam) was diluted 1:1000 for detection of SM22α, eGFP,
actin, and VE cadherin (CD144). After several washing steps
with TBS-T, binding of the primary antibody was visualized
using a HRP-coupled secondary antibody (Bio-Rad) and ECL
Plus reagent (GE Healthcare, Munich, Germany). Chemilumi-
nescence was visualized using the molecular imager Chemi Doc
XRS from Bio-Rad.
BrdU Proliferation and Resazurin Viability Assay.
Proliferation and viability of cells were assessed performing
BrdU ELISA (Cell Proliferation ELISA, Roche, Basel, Switzer-
land) and resazurin viability assays (Fluorometric Cell Viability
Kit I from PromoKine GmbH, Heidelberg, Germany),
respectively. Brieﬂy, after seeding in 96-well plates and culture
for 24 h cells were treated with 100 nM paclitaxel (Santa Cruz
Biotechnology, Santa Cruz, CA, USA) for 5 h in basal media.
Afterward the cells were washed with PBS, and the medium was
replaced with corresponding growth medium (basal medium
containing culture supplements). After incubation for 24 h at
37 °C the BrdU-labeling solution was added. For detection of
cell viability, the medium was replaced by resazurin containing
growth medium after 48 h treatment, then the cells were
incubated for additional 2 h at 37 °C. Subsequently, the formed
resoruﬁn was quantiﬁed using the Inﬁnite200 microplate reader
(Tecan, Crailsheim, Germany) at an excitation wavelength of
530 nm and an emission wavelength of 590 nm. Cells treated
with solvent served as the control. After washing the cells with
PBS the amount of incorporated BrdU was quantiﬁed
according to the manufacturer’s instructions. Chemilumines-
cence was determined using the Inﬁnite 200 microplate reader.
■ RESULTS
Expression of SM22α in Human Vascular Cells. To
verify the cell-speciﬁc activity of the promoter chosen as an
expression driving force in the herein proposed adenoviral
construct, SM22α (transgelin) expression was determined
comparing HCAECs and HCASMCs isolated from three
diﬀerent individuals. Quantitative real-time PCR revealed
signiﬁcantly higher mRNA levels of transgelin in HCASMCs
(data not shown). In accordance, enhanced protein expression
of SM22α was observed in HCASMCs, which were also tested
for expression of smooth muscle actin as an additional marker
protein and expression of VE-cadherin an endothelial marker,
performing Western blot analysis (Figure 1A). Similar results
were obtained by immunoﬂuorescent staining of SM22α
comparing HCASMCs and HCAECs (Figure 1B).
Comparing Adenoviral Gene Transfer in Diﬀerent Cell
Types. The eﬃcacy of gene transfer was tested in diﬀerent
cellular models. Therefore expression of eGFP was assessed
after infection with adenoviruses containing the coding region
under control of the SM22α-promoter fragment (pAD-SM22-
eGFP) or the commonly in molecular biology used CMV-
promoter (pAD-CMV-eGFP), respectively. As shown in Figure
2A gene transfer was most eﬃcient in HCASMCs. Especially,
murine cardiomyocytes (HL-1) and endothelial cells HCAECs
exhibited very low infection eﬃcacy compared to HCASMCs
even if using CMV-promoter driven eGFP expression. In
contrast, canine MDCKII and human A549 cells were well
responsive to adenoviral gene transfer. Importantly, after
infection with pAD-SM22-eGFP only little ﬂuorescence was
observed in all cells but HCASMCs. As shown in Figure 2B,
similar results were obtained performing Western blot analysis.
In detail, after infection with 50 pfu/cell HCASMCs exhibited
Figure 1. Detection of SM22α (transgelin) in human coronary artery smooth muscle cells (HCASMCs) and endothelial cells (HCAECs). (A)
Protein lysates of cultured primary HCASMCs and HCAECs obtained from two diﬀerent individuals were used for Western blot analysis of SM22α
(transgelin) expression; smooth muscle actin (SM-actin) was used as a smooth muscle cell marker, while vascular endothelial cadherin (VE-
cadherin) served as a endothelial marker. (B) SM22alpha was also detected by immunoﬂuorescent staining of cultured HCASMCs and HCAECs. In
the case of the control staining the primary antibody was omitted.
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highest expression of eGFP, while HCAECs exhibited only
modest levels of the protein even if driven by the CMV-
promoter. Importantly, in the presence of the SM22α-promoter
eGFP expression was nearly abolished in MDCKII and A549.
However, there was some eGFP detectable in pAD-SM22-
eGFP infected endothelial cells.
OCT1 Activity after Adenoviral Transfer in MDCKII
Cells. MDCKII cells are often used to characterize transporters
in vitro;15 therefore we tested the expression and activity of the
organic cation transporter OCT1 in those cells after adenoviral
gene transfer. At ﬁrst, expression of the transporter was
determined by Western blot analysis after infection with
diﬀerent viral concentrations (ranging from 5 to 50 pfu/cell)
revealing intensiﬁed expression in the presence of increasing
virus concentrations (Figure 3A). In addition the transporter
was located in the plasma membrane of infected MDCKII cells
as determined by immunoﬂuorescent staining. Importantly, no
signal was observed in MDCKII cells infected with pAD-SM22-
OCT1 (Figure 3B). This is in accordance with following
ﬁndings on the enhanced uptake of the prototypical OCT1-
substrate MPP+ in MDCKII cells infected with the virus
encoding the transporter under the control of the CMV
promoter (Figure 3C).
Transport Activity in Diﬀerent Cellular Models. It was
aim of the study to determine whether adenoviral gene transfer
could be used to enhance cellular accumulation and therefore
Figure 2. Adenovirus mediated gene transfer comparing diﬀerent cellular models. Cells were cultured on coverslips, after treatment with adenovirus
cells were ﬁxed and cellular morphology was determined by HE-staining (upper panel). No signiﬁcant impact on cellular morphology was observed
after adenoviral infection with 50 pfu/cell; in control cells the virus was omitted. Expression of GFP was visualized by ﬂuorenscence microscope 48 h
after infection with 50 pfu/cell of pAD-SM22-eGFP or pAD-CMV-eGFP, respectively.
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eﬃcacy of substrate drugs in a cell type speciﬁc manner. To test
cellular accumulation in presence of OCT1, cells were infected
with adenoviruses containing the coding sequence of this
transporter either under the control of the CMV-promoter or
the control of the SM22-promoter, followed by transport
studies with two diﬀerent prototypical substrates of OCT1,
namely, [3H]-MPP+ and [14C]-TEA. As shown in Figure 4 all
cell types tested exhibited enhanced uptake of MPP+ in the
presence of pAD-CMV-OCT1, with the highest increase in
HCASMCs (% uptake of pAD-CMV-eGFP, mean ± SD; 451.7
± 20.9%), even if signiﬁcantly lower compared to the CMV
promoter those cells also exhibited enhanced intracellular
accumulation when infected with pAD-SM22-OCT1 (392.7 ±
13.2%). Similar results were obtained in murine cardiomyocytes
(pAD-CMV-OCT1 infected 220.5 ± 33.0; pAD-SM22-OCT1
infected 259.6 ± 14.1%). However, in HCAECs infected with
pAD-CMV-OCT1 uptake of MPP+ was increased by about 2-
fold (206.9 ± 19.9%), whereas no statistically signiﬁcant uptake
was observed after infection with pAD-SM22-OCT1 (144.0 ±
31.2%). Similar results were obtained for TEA (data not
shown).
OCT1 Enhances Antiproliferative Activity in HCASMCs
of the Substrate Drug Paclitaxel. Paclitaxel is one of the
previously reported cytotoxic OCT1 substrates.11 To determine
the impact of adenoviral-mediated OCT1-expression on the
antiproliferative eﬃcacy of this compound, HCASMCs and
HCAECs were infected with pAD-CMV-OCT1 or pAD-SM22-
OCT1 and treated with 100 nM paclitaxel. As shown in Figure
5 in the presence of the CMV-promoter driven OCT1 both cell
types exhibited enhanced eﬃcacy of the mitotic inhibitor
compared to cells infected with the control virus pAD-CMV-
lacZ (proliferation fold of control cells; mean ± SD;
HCASMCs 0.54 ± 0.08, HCAECs 0.76 ± 0.11). Importantly,
the inﬂuence of OCT1 was not present in HCAECs infected
with pAD-SM22-OCT1 (0.9 ± 0.1), while HCASMCs
exhibited enhanced antiproliferative activity of paclitaxel (0.56
± 0.13).
Figure 3. Detection and functional characterization of OCT1 in MDCKII cells. Expression of OCT1 was determined by Western blot analysis 48 h
after infection with diﬀerent amounts of pAD-CMV-OCT1 (ranging from 5 to 50 pfu/cell). Localization of the transporter in the basolateral
membrane of polarized MDCKII-cells was observed performing immunoﬂuorescent staining with an OCT1-speciﬁc antibody; no signiﬁcant
membrane staining was observed in cells infected with 50 pfu/cell of pAD-SM22-OCT1 or the control vector pAD-CMV-lacZ. Signiﬁcant uptake of
MPP+ was observed in cells infected with OCT1 driven by a CMV promoter.
Figure 4. Uptake of substrate drugs after adenoviral transfer of the organic cation transporter OCT1. Diﬀerent cell lines were infected with pAD-
CMV-OCT1 or pAD-SM22-OCT1 50 pfu/cell. Forty-eight hours after infection transport activity was determined measuring the uptake
radiolabeled MPP+ after 5 min incubation (**p < 0.005, *p < 0.05, Student’s t-test, n = 3).
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■ DISCUSSION
The use of drug delivery devices, such as stents, in the
treatment of coronary atherosclerosis is clinically well-
established and is the basis of the herein tested concept of a
transporter/substrate combination to target drug eﬀects. It was
aim of the study to provide a proof of concept that changing
the pharmacokinetics of a drug by the means of adenoviral gene
expression can be used to enhance cellular speciﬁcity. In
accordance, we were able to show in vitro that adenoviral
expression of the human organic cation transporter 1 (hOCT1)
signiﬁcantly increases uptake and thereby antiproliferative
activity of the substrate paclitaxel in smooth muscle cells.
The interaction of paclitaxel with this particular transporter has
been previously reported by Gupta et al. showing that OCT1-
expressing cell lines and OCT1-transfectants exhibit higher
susceptibility to cytotoxic eﬀects of paclitaxel compared to
OCT1-negative cells.11 In the case of the vascular system,
where target and nontarget cells, namely, smooth muscle and
endothelial cells, respectively, of a cytotoxic compound are in
very close vicinity, a cell-speciﬁc driving force for gene
expression is needed to realize the concept of the trans-
porter−drug combination strategy. The SM22α promoter is a
widely accepted tool for deletion or overexpression of genes in
smooth muscle cells.16−18 We also observed muscle cell speciﬁc
activity when quantifying the OCT1 transport function.
However, SM22α-driven expression was not as restricted to
HCASMCs, when assessing for eGFP expression, suggesting at
least some activity of the SM22α promoter in cell lines other
than HCASMCs in vitro. The speciﬁcity and potency of
SM22α-promoter driven gene expression after balloon catheter
based delivery of an adenovirus has recently been tested in vivo,
showing GFP expression in smooth muscle cells after treatment
of swine. In this particular study Pankajakshan et al. observed
muscle cell speciﬁc expression after short-term exposure with a
virus coated balloon.19 A diﬀerent approach to enhance cellular
selectivity of an adenoviral based transfection system would be
the use of transductional targeting. The clinical use of
adenovirus type 5 as a gene therapeutic tool at least for
systemic administration is hampered by the liver tropism of the
virus, which is associated with signiﬁcant hepatotoxicity. The
tropism is mediated by higher expression of the coxsackie and
adenovirus receptor (CAR) and other membrane proteins
assumed to be responsible for cellular entry of the virus in
hepatocytes compared to other tissues.20 Previous studies have
tested modiﬁcations in the knob domain of the adenoviral ﬁber
the region assumed to bind to the CAR receptor, which have
resulted in diﬀerent transduction eﬃcacy of the adenovirus.21 In
uterine leiomyoma, a tumor entity deriving from smooth
muscle cells, enhanced transduction eﬃcacy was observed using
an adenovirus with a modiﬁed RGD sequence in the adenoviral
ﬁber.22 The integration of ﬁber modiﬁed adenovirus with
restricted promoter activity into a local drug delivery device
seems of high potential for future developments in gene
therapy, which should not be limited to the vascular system.
Several studies have previously tested the combination of
adenovirus with local delivery devices in vivo. Ohno et al. ﬁrst
provided evidence that changing pharmacokinetics of a
cytotoxic compound could be used to target drug eﬀects after
angioplasty. Indeed, the authors combined angioplasty
mediated adenoviral gene transfer of the herpes virus thymidine
kinase gene, an enzyme converting the purine analogue
ganciclovir to its biologically active metabolite with the systemic
administration of this compound, and showed signiﬁcantly
reduced vascular smooth muscle cell proliferation after
adenoviral infection.23 Importantly, metabolically activated
ganciclovir has no impact on nondividing cells, thereby
restricting the pharmacodynamic eﬀect to thymidine kinase
expressing and proliferating cells. However, the authors did not
clearly report any data on the impact of ganciclovir treatment
on endothelial cells in their animal study. Importantly, in the
same study the authors observed no signiﬁcant accumulation of
the virus in other tissues, such as liver, suggesting that viral
eﬀects are limited to the vascular system.
It seems noteworthy, that in the above-mentioned study the
authors used the two-balloon catheter technique which had
been previously reported by Willard et al. as the most eﬃcient
catheter based local delivery device for gene transfer.24
Performing this procedure, the virus solution is injected in a
chamber between an inﬂated proximal and distal compartment
of the balloon. Using a similar technique Laitinen et al. were
able to show adenovirus-mediated gene transfer to the vascular
wall in humans in vivo. Even if rather low gene transfer eﬃcacy
(0.04−5% of all arterial cells) was reported, expression of the
transgene was observed in all cell types including smooth
muscle and endothelial cells.25 However, our in vitro data
suggest very low adenovirus-mediated gene expression in
HCAECs compared to HCASMCs even if using a CMV-
promoter as driving force. This low infection eﬃcacy is in
accordance with ﬁndings by Lenaerts et al. showing lower virus
binding to endothelial cells,26 thereby explaining lower gene
expression after adenoviral infection. In the following years the
therapeutic eﬃcacy of diﬀerent transgenes including growth
factors (e.g., VEGF), synthetic peptides,27 and other proteins
functional in cell proliferation or migration28 have been tested.
However, most of the studies were performed exposing the
vasculature directly after balloon injury to the virus, although it
had been reported that gene delivery is most eﬃcient 7−8 days
after balloon injury, thereby suggesting that a long-term
exposure with the a gene delivery device coated with adenovirus
would be most eﬃcient.27,29 However, it cannot be excluded
that this observed rather short period of gene expression after
viral delivery would also be suﬃcient for a transporter-mediated
cell speciﬁc drug targeting. Particularly when considering the
drug release proﬁle of the ﬁrst generation paclitaxel stent
TAXUS Express,30 where the drug release proﬁle consisted of a
Figure 5. Impact of OCT1 on antiproliferative activity of paclitaxel.
Proliferation of HCASMCs and HCAECs was determined after viral
infection. 48 hrs after infection cells were treated 5 h with 100 nM
paclitaxel. 48 h after treatment the proliferation rate was determined
performing a BrdU-ELISA (**p < 0.005, *p < 0.05, Student’s t-test, n
= 6).
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48 h burst followed by a 10 day period of slow drug release,
which despite this rather short-term drug release proﬁle
resulted in poor endothelialization.31
Since the study of Laitinen et al. in 1998, the ﬁeld of
biomedical engineering has signiﬁcantly evolved, now providing
other solutions for adenoviral gene transfer including
bioabsorbable poly(L-lactide) (PLLA)/poly(ε-caprolactone)
(PCL) stents,32 nanobots (nanoparticles based on the
biodegradable poly(lactide-co-glycolide) (PLGA)),33 that have
been shown to serve as potent delivery devices for adenovirus.
An alternative to the use of the adenovirus-based technology
would be the use of plasmid/liposome solutions. It has been
previously reported that both methods resulted in expression of
the transgene in humans. Importantly, Makinen et al. even
reported results on a clinical study in humans where VEGF was
expressed by both methods.34 In the eight year follow up, no
signiﬁcant diﬀerence was observed for the two techniques of
VEGF gene delivery determining the clinical outcome.35
It might be hypothesized that the transporter used in a
transporter/drug concept based drug delivery devices is
exchangeable. Indeed, there are several members of the
superfamily of the SLC transporter that have been shown to
transport cytotoxic compounds including organic anion trans-
porters such as OATP1B3 which has been reported to facilitate
uptake SN-38 or docetaxel,36,37 or such as OAT2 which
increases cellular accumulation of 6-ﬂuouracil or paclitaxel
(summarized in ref 38).
In conclusion, adenovirus-mediated expression of uptake
transporters to enhance accumulation and thereby pharmaco-
dynamics of substrate drugs as shown for the SMC-speciﬁc
expression of OCT1 and the enhanced activity of paclitaxel in
those cells is not limited to cationic substrates. In current
approaches to identify potential novel candidates for drug
eluting stents primary human smooth muscle and endothelial
cells are screened. With the transporter/drug-concept, the
speciﬁcity of cytotoxic compounds could be enhanced by
speciﬁcally increasing the mechanism of uptake. It seems
noteworthy that the combination of delivery device and
adenovirus-mediated transporter expression even seems of
potential for other therapeutic strategies where cellular
enrichment of a compound would improve the outcome or
reduce unwanted side eﬀects.
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Clinical success of coronary drug-eluting stents (DES) is hampered by simultaneous reduction of smoothmuscle cell
(HCASMC) and endothelial cell proliferation due to unspeciﬁc cytotoxicity of currently used compounds. Previous
in vitro data showing SMC-speciﬁc inhibition of proliferation suggested that statins may be suitable candidates for
DES. It was aim of this study to further investigate statins as DES drug candidates to identify mechanisms contribut-
ing to their cell-selectivity. In vitro proliferation assays comparing the inﬂuence of various statins on HCASMC and
endothelial cells conﬁrmed that atorvastatin exhibits HCASMC-speciﬁcity. Due to similar expression levels of the
drug target HMG-CoA reductase in both cell types, cellular accumulation of atorvastatin was assessed, revealing en-
hanced uptake in HCASMCmost likely driven by signiﬁcant expression of OATP2B1, a known uptake transporter for
atorvastatin. In accordancewith theﬁnding that endogenousOATP2B1 inﬂuenced cellular accumulation inHCASMC
we used this transporter as a tool to identify teniposide as new DES candidate drug with HCASMC-speciﬁc effects.
We describe OATP2B1 as a determinant of pharmacokinetics in the coronary artery. Indeed, endogenously
expressedOATP2B1 signiﬁcantly inﬂuences the uptake of substrate drugs, thereby governing cell speciﬁcity. Screen-
ing of candidate drugs for interaction with OATP2B1 may be used to promote SMC-speciﬁcity.
© 2015 Elsevier Inc. All rights reserved.
1. Introduction
Atherosclerosis is a major risk factor of coronary artery disease
which ﬁnally may lead to myocardial infarction [1]. In order to restore
the blood ﬂow in obstructed arteries the percutaneous coronary trans-
luminal angioplasty (PTCA) is commonly used in clinics. However,
after dilatation a variety of cellularmechanisms take place including ag-
gregation of platelets, release of growth factors, inﬁltration of inﬂamma-
tory cells, and proliferation and migration of smooth muscle cells [2,3]
ﬁnally resulting in restenosis of the vessel often with fatal impact on
the outcome. In order to prevent restenosis after transluminal artery di-
latation the implantation of bare metal stents (BMS) was introduced in
this clinical procedure. Although prospective multicenter studies dem-
onstrated an improved clinical outcomewith reduced rates of restenosis
after stenting [4,5], success of BMS was signiﬁcantly hampered by the
manifestation of subacute thrombosis and in-stent restenosis [6]. In-
deed, it is assumed that the injury of the vesselwall during stent deploy-
ment triggers an inﬂammatory process resulting in production and
secretion of various growth factors that stimulate smooth muscle cell
proliferation resulting in the pathological phenomenon of neointima
formation [2,7–9]. The ﬁrst-generation drug-eluting stents (DES), load-
ed with sirolimus (Cypher, Cordis, Warren, New Jersey, USA) or pacli-
taxel (Taxus, Boston Scientiﬁc, Natick, USA) were introduced with the
idea that cytotoxic compounds inhibit the formation of a neointima
due to their antiproliferative activity, thereby reducing the adverse
event of in-stent restenosis [10,11]. In accordance with this notion are
ﬁndings of controlled clinical trials reporting reduced in-stent late
lumen loss and in-stent angiographic restenosis comparing DES and
BMS [12]. However, the adverse event of stent thrombosis remains a
major safety problem, where late stent thrombosis (N1 year after
stenting) ismore likely after implantation of DES [13,14]. Numerous fac-
tors have been associated with the risk of thrombotic events in DES-
treated arteries, including reduced endothelialization of the stent strut
due to inhibition ofmigration and proliferation of endothelial cells. Sub-
sequent developments of DES focused on agents demonstrating not
only antiproliferative, but also enhanced anti-inﬂammatory activity as
observed with everolimus or zotarolimus, which are both currently
used on second-generation DES. However, even if there is a lower risk
of late stent thrombosis in patients treated with second-generation
DES the incidence of this adverse event has not been abolished [15]. De-
spite the fact that limus derivatives reduce inﬂammation after stenting,
from a pharmacological perspective there is still the need for
Vascular Pharmacology 72 (2015) 25–34
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compounds which speciﬁcally inhibit themigration and proliferation of
smooth muscle cells without affecting endothelial cells in order to en-
hance healing of vascular implants.
One approach to improve the outcome of DESmay be the use of drugs
showing beneﬁts in therapy of atherosclerosis. Several studies have pre-
viously reported an improved clinical outcome of patients orally treated
with statins during the time of DES deployment. Especially the treatment
with atorvastatin orﬂuvastatin has been associatedwith a reduced risk of
adverse cardiac events and other ischemia-related outcomes in patients
undergoing PTCA [16,17], thereby being the basis for previous reports
suggesting that statin-coated stents may be an option for improved clin-
ical outcome [18,19]. In this context, it seems noteworthy that several
in vitro and in vivo studies have reported a positive impact of delivery de-
vices coatedwith statins. Particularly, for cerivastatin a pronounced effect
on smoothmuscle cell proliferation andmigration [20]without impeding
endothelial cell proliferation has been shown [21], supported by in vivo
ﬁndings in a porcine coronarymodel [22]. Even if statins are all primarily
targeting HMG-CoA reductase thereby modulating cholesterol levels,
there are signiﬁcant differences in their physicochemical and pharmaco-
kinetic properties, which include passive permeability and active trans-
port [23]. Assuming that distribution in the area of the coronary artery,
deﬁned as microcompartment, surrounding the drug-delivery devices
also depends on passive diffusion or active transport those mechanisms
may signiﬁcantly inﬂuence cell-type speciﬁcity of drugs used on DES. In
order to test this hypothesis we compared the impact of different statins
on cellular proliferation, showing pronounced differences comparing
smooth muscle and endothelial cells.
The aim of the studywas to investigate whether cellular uptakemay
be a determinant of pharmacodynamics of statins in the micro compart-
ment of the vesselwall, andwhether transport by amembrane transport-
ermight be predictive for cell speciﬁcity of a compound used on coronary
drug delivery devices.
2. Methods
2.1. Materials
[3H]-atorvastatin (speciﬁc activity 10 Ci/mmol), [3H]-atorvastatin
lactone (speciﬁc activity 10 Ci/mmol) and [3H]-estrone 3-sulfate (spe-
ciﬁc activity 50 Ci/mmol) were obtained from Hartmann Analytic
(Braunschweig, Germany). Mevastatin, pravastatin, and simvastatin
were purchased from Sigma-Aldrich (Deisenhofen, Germany) and
cerivastatin from Bayer (Leverkusen, Germany). Farnesyl pyrophos-
phate and geranylgeranyl pyrophosphate were obtained from Santa
Cruz Biotechnology, Inc. (Santa Cruz, USA) and atorvastatin from Pﬁzer
Pharma (Karlsruhe, Germany). All other chemicals were obtained from
Sigma-Aldrich (St. Louis, USA) unless otherwise stated.
2.2. Cell culture
Human coronary artery smooth muscle cells (HCASMC) and endo-
thelial cells (HCAEC), isolated fromdifferent human individuals and gen-
ders, and their optimized media i.e., Smooth Muscle Cell Growth
Medium 2 and Endothelial Cell Growth Medium MV were obtained
from PromoCell GmbH (Heidelberg, Germany). Cells were cultivated in
a humidiﬁed atmosphere at 37 °C and 5% CO2 from passage four to ten.
For proliferation assays, cells were seeded in 96-well plates at a density
of 5 × 103 cells/well. After 24 h in growth medium, HCASMC or HCAEC
were maintained for further 24 h in basal medium (PromoCell GmbH)
supplementedwith only 0.05% or 0.5% FCS, respectively. To simulate cel-
lular stimulation after stent implantation, cells were then treated with
growth medium in presence or absence of the respective drug for 48 h.
For transport studies and expression analysis cells were seeded in re-
spective well plates at a density of 1.2 × 104 cells/cm2. Madin–Darby ca-
nine kidney II (MDCKII) cells overexpressing OATP2B1 as previously
reported [24] were cultivated in Dulbecco's modiﬁed Eagle medium
containing 10% fetal calf serum, 1% GlutaMax and 250 μg/ml Hygromycin
B, both obtained from Life Technologies (Carlsbad, USA), at 37 °C and 5%
CO2.
2.3. Bromodesoxyuridine (BrdU) cell proliferation assay
Cell proliferation of HCASMC and HCAEC in the presence of statins
was determined using the commercially available BrdU Cell Prolifera-
tion Kit (Roche, Basel, Switzerland). In brief, BrdU labeling solution
was added to the medium after 24 h treatment followed by incubation
for 24 h. Subsequently, BrdU ELISA was performed according to the
manufacturer's instructions and luminescence was measured with the
microplate reader (Inﬁnite® 200 Pro-Tecan, Männedorf, Switzerland).
Cells treated with the solvent served as control. Data are presented as
percent of control.
2.4. Adenoviral infection
For adenoviral infection the previously reported Ad-OATP2B1 [25]
was used. To study the inﬂuence on cell proliferation, HCASMC were
seeded in 96-well plates 24 h prior to infection with 50 pfu/cell Ad-
OATP2B1 followed by incubation with atorvastatin for 48 h. For short-
time incubation with teniposide, cells were treated for 10 min, washed
with PBS and cultivated in growth medium for 48 h. Transport activity
in HCASMC and HCAEC was assessed 48 h after adenoviral infection.
Cells infected with Ad-lacZ served as reference for all experiments if
not otherwise stated.
2.5. RNA isolation and quantitative real-time polymerase chain reaction
(qRT-PCR)
Total RNA from six different donors of both naïve HCASMC and
HCAEC was isolated using NucleoSpin® RNA (Machery-Nagel, Düren,
Germany) and reverse transcribed with the High Capacity cDNA Re-
verse Transcription Kit (Life Technologies) according to the manufac-
turer's instructions. For qRT-PCR, we used TaqMan® gene expression
assays from Life Technologies detecting HMGCR (Hs00168352_m1),
18S rRNA (Hs99999901_s1), or GAPDH (4326317E). PCR reactions
were carried out using the Viia 7™ (Life Technologies). Expression rela-
tive to human liver was calculated using the ΔΔCt-method.
2.6. Immunoblot analysis
For Western blot analysis cells were harvested in 100 μl of the com-
mercially available RIPA buffer supplemented with 10 μg/ml aprotinin
and 10 μg/ml leupeptin. Protein content in cell lysate was quantiﬁed by
a bicinchoninic acid assay (Pierce, Thermo Fisher Scientiﬁc Inc., Rockford,
USA). Protein samples were separated by SDS-PAGE and electro-
transferred to nitrocellulose membranes using a Tank blotting system
(Bio-Rad Laboratories, Berkeley, USA). After protein transfer, membranes
were placed in 5%-FCS in TBS-T (0.25 M Tris–base, 0.026 M KCl, 0.04%
Tween 200) for 1 h prior to incubation with the primary antibody. The
antibodies usedwere anti-HMGCR (sc-27578, 1:2000 Santa CruzBiotech-
nology, Inc.), anti-β-actin (sc-1616, 1:2000 Santa Cruz Biotechnology,
Inc.), anti-van Willebrand factor (vWF, ab6994, 1:5000 Abcam® Cam-
bridge, UK) and anti-α-smooth muscle actin (α-SM-actin, ab7817,
1:2000 Abcam®) diluted in TBS-T supplemented with 0.5% BSA. The pre-
viously reported anti-OATP2B1 serum [24] was used in a dilution of
1:5000. Incubation was performed at 4 °C overnight followed by several
washing steps with TBS-T and incubation with the respective HRP-
labeled secondary antibody for 1 h at room temperature. Luminescence
was visualized using the ECLWestern blotting substrate (Pierce, Thermo
Fisher Scientiﬁc Inc.) and digitalizedwith the ChemiDocXRS system (Bio-
Rad Laboratories). Densitometrywas conducted using Image Lab 4.1 soft-
ware from Bio-Rad Laboratories.
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2.7. Transport studies
For uptake studies conﬂuent layers of naïve HCASMC and HCAEC,
cells were incubated at 37 °C for 5 min with 1 μM atorvastatin or
1 μM atorvastatin lactone supplemented with [3H]-atorvastatin
(100,000 dpm/well) or [3H]-atorvastatin lactone (100,000 dpm/well),
respectively, solved in incubation buffer (0.14 M NaCl, 5 mM KCl,
1.2 mMMgSO4, 1 mM KH2PO4, 1.5 mM CaCl2, 5 mM glucose, 12.5 mM
HEPES, pH 7.3). After incubation cells were washed three times with
ice cold PBS and lysed in 0.2% SDS–5mMEDTA solution. Intracellular ac-
cumulation of radioactivity was quantiﬁed using a liquid scintillation
counter (type 1409, LKBWallac, Turku, Finland). The amount of atorva-
statin and atorvastatin lactone was related to the protein content of the
respective sample and is presented as fmol/μg protein. For functional
characterization of OATP2B1 after adenoviral infection, HCASMC were
incubated with 1 μM estrone 3-sulfate (E1S) for 5 min in the presence
of [3H]-E1S (100,000 dpm/well) 48 h after infection with 50 pfu/cell
Ad-OATP2B1 or Ad-lacZ. Inhibitors of OATP2B1were identiﬁed in uptake
studies using MDCKII-OATP2B1 cells. Therefore, cells were exposed to
the cytotoxic drugs (each 10 μM) or increasing concentrations of statins
in the presence of [3H]-E1S for 10min. The inhibition of E1S uptake by in-
cubation with teniposide (1, 10, and 100 nM) after adenoviral infection
with Ad-OATP2B1 in HCASMC was detected as described above. Inhibi-
tion of E1S uptake is presented as the percentage of the values obtained
for control cells.
2.8. Statistical analysis
Data are represented as means ± standard deviations (SD), if not
otherwise stated of at least three independent experiments performed
in triplicates and analyzed using Student's t-test or one-way ANOVA
comparing more than two groups. Statistical signiﬁcance was deﬁned
as p-value b 0.05. Graphs and calculations (IC50) were performed
using GraphPad Prism© software (GraphPad Software, Inc., La Jolla,
USA).
3. Results
3.1. Impact of statins on cell proliferation
In order to test the idea of pharmacokineticmechanisms inﬂuencing
cell speciﬁcity of DES drugs, we searched for a statin exerting anti-
proliferative activity in smooth muscle cells, which would translate
into inhibition of neointima formation, with less activity in endothelial
cells. Accordingly, the impact of different statins on proliferation of en-
dothelial (HCAEC) and smooth muscle cells (HCASMC) was compared,
treating primary cells for 48 h and assessing the status of proliferation
by BrdU ELISA. Incubation of both HCAEC and HCASMC with simvastat-
in, pravastatin, cerivastatin, mevastatin, or atorvastatin revealed vari-
able effects on proliferation (in % of DMSO treated cells; mean ± SD,
[Fig. 1A]). In detail, cerivastatin efﬁciently inhibited proliferation of
both cell types (HCASMC 12.3 ± 10.5% vs. HCAEC 19.8 ± 19.7%). A
much lower, but also non-cell-type-speciﬁc impact on proliferation
was observed for simvastatin (HCASMC 66.8 ± 41.4% vs. HCAEC
61.7 ± 48.7%), mevastatin (HCASMC 69.8 ± 4.8% vs. HCAEC 65.3 ±
22.5%), and ﬁnally pravastatin (HCASMC 106.0 ± 22.1% vs. HCAEC
93.9 ± 31.6%). For atorvastatin however, we observed cell speciﬁcity,
with signiﬁcantly higher inhibition of HCASMC proliferation (45.6 ±
25.2%) compared to endothelial cells (82.5 ± 3.3%; *p b 0.05, Student's
t-test). Those ﬁndings are in accordancewith IC50 values of atorvastatin
determined incubating HCASMC and HCAEC. As shown in Fig. 1B, the
calculated IC50 value was about 7-fold lower in HCASMC (0.62 μM; CI
95% 0.43–0.89 μM) compared to HCAEC (4.45 μM; CI 95% 2.19–
9.12 μM).
3.2. The involvement of HMC-CoA reductase in atorvastatin-induced
cellular effects
Statins exert so called pleiotropic activity mediated by intermediate
products of the cholesterol pathway (compare Fig. 2A),where the prima-
ry target of statins, theHMG-CoA reductase (HMGCR) is a key enzyme. It
may therefore be assumed that differences in cellular expression of this
enzyme contribute to the observed cell speciﬁcity of atorvastatin. How-
ever, quantiﬁcation of expression in HCASMC and HCAEC performing
qRT-PCR as shown in Fig. 2C revealed comparable levels of HMGCR-
mRNA in both cell types (HCASMC vs HCAEC as % of expression in
human liver; mean ± SD; 237.7 ± 73.1% vs. 273.3 ± 60.8%). Similar re-
sults were obtained for protein expression of HMGCR performingWest-
ern blot analysis comparing whole protein lysates of HCASMC and
HCAEC isolated from three individuals (Fig. 2D). In addition, the inﬂu-
ence of intermediate products of the cholesterol pathway, namely
geranylgeranyl pyrophosphate (GGPP), farnseyl pyrophosphate (FPP),
andmevalonatewas assessed in order to examinewhether the observed
atorvastatin induced antiproliferative effect is mediated by changes in
this pathway. HCAEC and HCASMC were incubated with 1 μM or 5 μM
atorvastatin, respectively; those concentrations were chosen to obtain
a comparable effect in both cell types, thereby accounting for the ob-
served differences in IC50 values (Fig. 1B). As shown in Fig. 2B, the anti-
proliferative activity of 1 μM atorvastatin in HCASMC (proliferation % of
DMSO treated cells, mean±SD; 51.6±12.5%)was signiﬁcantly reduced
in presence of GGPP (87.6±6.5%; *p b 0.05, one-way ANOVA). However,
no statistically signiﬁcant impact was observed for FPP (51.3 ± 22.8%),
mevalonate (61.0±23.4%), or cholesterol (52.6±16.5%). Similar results
were observed in HCAEC treatedwith 5 μMof atorvastatin to also induce
cytostatic effects in those cells.
3.3. Uptake of atorvastatin in HCASMC and HCAEC
To test whether the observed cell speciﬁcity of atorvastatin involves
differences in cellular accumulation, the uptake of [3H]-atorvastatin or
its pharmacological inactive metabolite [3H]-atorvastatin lactone in
HCASMC and HCAEC was compared.
As shown in Fig. 3A, HCASMC exert a 2-fold higher cellular uptake
of atorvastatin (mean ± SD uptake in fmol/μg protein; 1.04 ± 0.08;
*p b 0.05, Student's t-test) compared to HCAEC (0.49 ± 0.23),
supporting the notion that pharmacokinetic properties might be a
determinant of cell speciﬁcity. No such effect was observed for the
atorvastatin metabolite. Indeed, even if the accumulating total
amount of atorvastatin lactone was higher no difference was
observed between both cell types (HCASMC 3.48 ± 0.76; HCAEC
2.27 ± 1.74).
3.4. Expression of OATP2B1 in HCASMC and HCAEC
Onemechanism contributing to changes in drug distribution is the ex-
pression of drug transporters. Oneuptake transporter previously reported
to transport atorvastatin is the organic anion transporting polypeptide
OATP2B1 [24]. In accordance with a potential role of OATP2B1 in
atorvastatin's cell speciﬁcity are our ﬁndings obtained using MDCKII-
OATP2B1 cells, where uptake of [3H]-estrone 3-sulfate (E1S) in presence
of 10 μMatorvastatinwas signiﬁcantly inhibited (4.5± 1.4%). Important-
ly, inhibition by cerivastatin (69.1 ± 12.0%) or simvastatin (56.7 ± 4.3%)
was much lower, while no inhibitory potency was observed for
mevastatin or pravastatin (Fig. 5A). In addition, densitometry of Western
blot signals detected for OATP2B1 using protein lysates isolated from four
individuals of both HCASMC and HCAEC revealed signiﬁcantly higher ex-
pression in HCASMC compared to HCAEC (mean± SD OATP2B1/β-actin;
HCASMC 0.92 ± 0.29 vs. HCAEC 0.40 ± 0.25,*p b 0.05, Student's t-test)
(Fig. 3B and C).
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3.5. Adenoviral-induced overexpression of OATP2B1 and its effect on
atorvastatin-induced antiproliferation
Hitherto our data support the idea that OATP2B1may be involved in
differences in cellular accumulation and therefore pharmacological ac-
tivity of atorvastatin. To support this hypothesis we tested whether en-
hanced expression of the transporter mediated by adenoviral infection
may result in increased antiproliferative activity of this compound.
Functionality of the transporter after infection of HCASMC was veriﬁed
showing higher uptake of the well-known OATP2B1 substrate [24],
estrone-3-sulfate (E1S) as shown in Fig. 4A. In addition, proliferation as-
says demonstrated higher antiproliferative activity of atorvastatin in
HCASMC overexpressing OATP2B1, resulting in a 10-fold lower IC50
value comparing cells infected with Ad-OATP2B1 (0.14 μM; CI 95%
0.06–0.28 μM) or the control virus Ad-lacZ (1.44 μM; CI 95% 0.58–
3.56 μM). Similar results were obtained infecting endothelial cells
with Ad-OATP2B1 (data not shown).
3.6. Teniposide as a candidate for cell-speciﬁc antiproliferative activity
in HCASMC
Assuming that endogenous expression of OATP2B1 is a determinant
of drug effects in HCASMC substrates of this transporter should exert
enhanced cell speciﬁcity. One possibility to identify potential substrates
is the screening for inhibition of uptake of a model substrate using
overexpressing cell lines. Accordingly we used MDCK II cells overex-
pressing OATP2B1 to test the impact of a variety of clinically used cyto-
static agents on the uptake of the model substrate estrone-3-sulfate
(E1S). The screening revealed melphalan (1.90-fold), paclitaxel
(1.85-fold), and teniposide (5.63-fold) as inhibitors of OATP2B1 mediat-
ed E1S-uptake (compare Fig. 5C).
In evidence that teniposide may be a substrate of OATP2B1 we
assessed the inﬂuence of this compound on arterial cells, demon-
strating that teniposide is a potent inhibitor of HCASMC prolifera-
tion (mean ± SD; 66.1 ± 10.8%) with little effect on HCAEC
(93.9 ± 8.6%; p b 0.05, Student's t-test) as shown in Fig. 6B. The
role of OATP2B1 in pharmacokinetics of teniposide was further sup-
ported testing the inﬂuence of heterologous expressed OATP2B1. As
shown in Fig. 6D, the incubation with 100 nM teniposide in presence
of OATP2B1 led to signiﬁcantly enhanced effects on proliferation
compared to control infected cells (Ad-lacZ vs. Ad-OATP2B1;
mean ± SD in %; 91.78 ± 9.12% vs. 71.99 ± 13.57%, *p b 0.05, Stu-
dent's t-test; n = 5) that is in accordance with data from uptake
studies showing a signiﬁcant inhibition of E1S by teniposide in
presence of OATP2B1 (73.11 ± 7.23% compared to DMSO treated
cells, *p b 0.05, one-way ANOVA).
4. Discussion
In this study we provide evidence that endogenous expression of the
uptake transporter OATP2B1 in human coronary smooth muscle cells
Fig. 1. Impact of statins on cell proliferation. (A) HCASMC and HCAEC were incubated with statins (each 1 μM) for 48 h and proliferation was determined by colorimetric BrdU ELISA.
Mean ± SD, n = at least 3 experiments in triplicates, *p b 0.05, Student's t-test. (B) HCASMC and HCAEC were incubated with increasing concentration of atorvastatin (0.01–25 μM)
48 h prior to the determination of cellular proliferation status. IC50 values were calculated using GraphPad Prism Software. Mean ± SD in a semi logarithmic plot; n = 5.
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(HCASMC) is a determinant of pharmacokinetics in the microcom-
partment of the vesselwall, resulting in enhanced cell-selectivity thereby
inﬂuencing efﬁcacy of substrate drugs. Indeed, testing the antiprolifera-
tive activity of atorvastatin revealed a signiﬁcantly higher impact on
smooth muscle cell proliferation compared to that of endothelial cells.
In accordance with previous ﬁndings where atorvastatin was described
as a high-afﬁnity substrate of OATP2B1 [24], we show that the cell-
speciﬁc activity of atorvastatin is associatedwith enhanced cellular accu-
mulation of this compound, which can be explained in part by a higher
expression of OATP2B1 in smoothmuscle cells. Adenovirus-driven over-
expression of OATP2B1 in HCASMC led to even higher sensitivity to ator-
vastatin; thereby further supporting the notion that cellular uptake
inﬂuences pharmacodynamics in this microcompartment. Using
OATP2B1 transport activity as a screening approach helped to identify
compounds with smooth muscle cell speciﬁc activity in vitro, thereby
introducing a preclinical tool for the identiﬁcation of compounds with
smooth muscle cell enhanced activity.
From a pharmacological point of few it is one of the major obstacles
for the development of DES to identify compounds speciﬁcally targeting
smooth muscle cells without inﬂuencing endothelialization of the stent
struts. This is in part based on the localization of target and non-target
cells in immediate vicinity of the drug delivery device and the use of
compounds with high passive permeability. One of the approaches to
enhance cell targeting may be the restricted loading on the drug de-
livery device, as previously reported, showing dual loading of stents
with atorvastatin on the luminal side and sirolimus on the abluminal
side [27]. In addition, derivatives of the lead compound sirolimus
and their inﬂuence on smooth muscle cell proliferation and viability
have been tested, showing a pronounced impact on proliferation
without affecting cell viability compared to cells treated with
Fig. 2. Inhibition of HMG-CoA reductase (HMGCR) by atorvastatin. (A) Mammalian cell mevalonate pathway ending in cholesterol biosynthesis adapted from Corsini et al. [26].
(B) HCASMC or HCAEC of three individuals were incubated with 1 μM or 5 μM atorvastatin, respectively, in presence of FPP, GGPP, mevalonate, and cholesterol (each 10 μM) and prolif-
eration was determined by BrdU ELISA. Mean ± SD, n = 5, *p b 0.01, one-way ANOVA with Dunnett's post-test compared to atorvastatin treated cells only. (C) Expression of HMGCR in
HCASMC and HCAEC was detected using TaqMan® gene expression assays. Data are shown as 2ΔΔCt normalized to 18S rRNA and GAPDH in % compared to expression in human liver.
(D) Protein expression of HMGCR, vWF, α-SM-actin, and β-actin was determined using whole cell lysate each (15 μg) from three different individuals of both HCASMC and HCAEC. Lu-
minescence was digitalized and densitometrically analyzed.
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paclitaxel, a compound demonstrating high cytotoxic effects [28,29].
Particularly, everolimus and zotarolimus have been proved to be potent
inhibitors of neointimal formationwhile supporting endothelial integri-
ty, thereby translating in a reduction of in-stent restenosis and better
re-endothelialization compared to ﬁrst generation DES or BMS in vivo
[30–33].
Understanding cellularmechanisms inﬂuencing pharmacodynamics
and -kinetics in the microcompartment of the vessel wall may signiﬁ-
cantly contribute to the identiﬁcation of novel compounds with im-
proved clinical outcome. One class of substances which has been
reported to inﬂuence the clinical outcome of patients undergoing per-
cutaneous intervention with stent deployment is the class of statins.
The observation that statins orally administered [17,34] reduce the
risk of restenosis was basis for subsequent preclinical studies ﬁnally
demonstrating that cerivastatin-eluting stents implanted in arteries of
pigs reduced neointimal hyperplasia without impairing endothelial
cell integrity [35]. Even if cerivastatin had been reported to exert a
higher effect on smooth muscle cell proliferation in nanomolar concen-
trations [21] our experiments failed to show this effect in presence of
higher concentrations using human cells. However, in our hands espe-
cially atorvastatin exerted enhanced antiproliferative potency in
HCASMC compared to HCAEC. Those ﬁndings are supported by a previ-
ous report of Korybalska et al. showing that atorvastatin did not impair
endothelial wound healing in an in vitro model of vascular injury [36].
Considering that there was no difference in expression of the primary
drug target HMG-CoA reductase comparing HCASMC and HCAEC we
ﬁrst focused on differences resulting from the pleiotropic activity of
statins. Indeed, beside their lipid-lowering effects, this drug class ex-
hibits anti-inﬂammatory, antiproliferative and anti-thrombotic activi-
ty [37,38]. It is well known that HMG-CoA reductase activity is
essential for proliferation of growth-stimulated cells [39]. Accordingly,
statins inhibit the formation of the isoprenoid intermediates farnesyl
pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP)
Fig. 3. Uptake of atorvastatin and atorvastatin lactone and expression of OATP2B1. (A) Uptake of [3H]-atorvastatin acid and [3H]-atorvastatin lactone in HCASMC and HCAEC was deter-
mined after 5 min incubation in naïve cells. Data are expressed as fmol/μg protein. Mean± SD, n= 3 in triplicates, *p b 0.05, Student's t-test. (B, C) Protein expression of OATP2B1 and β-
actin as loading control in HCASMC andHCAECwas determined byWestern blot analysis (B) using whole cell lysates of two individuals (each 10 μg) and densitometry (C)was conducted
using Western blot signals from four different donors of both HCASMC and HCAEC.
Fig. 4. Impact of adenoviral-driven overexpression of OATP2B1 in HCASMC. (A) HCASMC
were incubated with increasing concentration of atorvastatin (0.01–25 μM) 48 h after in-
fection with 50 pfu/cell Ad-OATP2B1 or Ad-lacZ. Proliferation status was determined by
BrdU ELISA 48 h after treatment. Mean ± SD, n = 3 conducted in triplicates from one in-
dividual. (B) Uptake of 1 μM estrone-3-sulfate supplemented with [3H]-E1S in HCASMC
was measured 48 h after infection with 50 pfu/cell Ad-OATP2B1 or Ad-lacZ. Data are pre-
sented as fmol/min/μg protein. Mean ± SD, n = 3 conducted in triplicates from one
individual.
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thereby modulating the GTPase activity of members of the Ras and Rho
family [40,41]. Particularly, inhibition of the RhoA geranylgeranylation
has been shown to result in an accumulation of inactive RhoA in the cy-
toplasm, which in turn increases the expression of the cell-cycle inhib-
itor p27kip1 resulting in a cell-cycle arrest in smooth muscle cells [37,
42]. In our study we observed a reversal of the atorvastatin-induced
antiproliferation by co-incubation with GGPP in HCASMC and HCAEC,
whereas no such effect was observed by incubation with FPP which
has beendemonstrated before in studies showing that FPP did not inﬂu-
ence the statin-induced cellular effects [43–45]. Farnesyl pyrophos-
phate is a precursor for synthesis of dolichols, cholesterol, or GGPP
and it mediates the farnesylation of proteins such as Ras, the latter not
being associated with cell proliferation and cell cycle progression. Due
to this it is obviously that FPP in a concentration of 10 μMwill not inhibit
the atorvastatin-induced antiproliferation. It also explains why
mevalonate did not diminish the effect of atorvastatin as mevalonate
is an upstream molecule of FPP. The antiproliferative action of atorva-
statin was furthermore not inhibited by cholesterol as demonstrated
by Porter et al. showing that proliferation of cells is independently of
cholesterol-synthesis [46]. However, our data are in line with different
studies comparing the inﬂuence of statins on endothelial and smooth
muscle cell viability, proliferation, and migration [21,36,47].
Although the inﬂuence of statins on cell-cycle control and modula-
tion of signal cascades has been demonstrated, the question whether
the activity of statins is mediated by pharmacokinetics in the
microcompartment of the vessel wall remained unanswered. It is
known that cellular processes such as the uptake and metabolism of
compounds modulate intracellular drug effects. The major mechanism
of cellular uptake is passive diffusion. This mechanism is modulated
by compound properties such as lipophilicity, molecular weight, and
H-bond acceptance to mention some of them [48]. Comparing the abil-
ity of statins passing membranes under physiological conditions, it has
been shown that simvastatin and cerivastatin have the highest lipophi-
licity, while pravastatin exhibits the lowest of the herein tested statins
[49]. However, considering that lipophilicity translates in high mem-
brane permeability by passive diffusion and thereby in enhanced intra-
cellular accumulation, then this substance property may not only
explain the observed enhanced antiproliferative activity of simvastatin
and cerivastatin compared to pravastatin, but also the lack of cell spec-
iﬁcity observed for those substances.
Another mechanism governing transmembrane transport is the ex-
pression and function of drug transporters. Especially uptake trans-
porters, facilitating cellular entry and thereby intracellular activity,
may alter cell speciﬁcity of their substrate drug, when differentially
expressed in target and non-target cells. One of the uptake transporters
known to be involved in the pharmacokinetics of statins is OATP2B1,
which apart from its expression in hepatocytes and enterocytes has
been detected in human platelets and cardiac endothelial cells [24,50].
The expression function of this transporter in myocytes is assumed to
inﬂuence drug effects such as the statin-induced myotoxicity — a side
effect associated with accumulation of statins in skeletal muscle [25].
The observed higher accumulation of atorvastatin inHCASMC can be
explained by our ﬁnding that smoothmuscle cells exhibit higher endog-
enous OATP2B1 expression compared to endothelial cells. From a
Fig. 5. Screening of cytotoxic drugs on OATP2B1-overexpressing MDCK II cells. (A, C) Cells were incubated for 10min with [3H]-E1S in the presence or absence of cyclosporin A (CsA), or
different cytostatic drugs (each 10 μM). (*p b 0.05, **p b 0.01, ***p b 0.001, one-way ANOVA). (B) Cells were incubated for 10 min with [3H]-E1S in the presence of simvastatin or
cerivastatin (0.01–100 μM). Graphs are presented as nonlinear regression. Data are presented as mean ± SD, n = 3 experiments conducted in triplicates.
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clinical perspective atorvastatin acid is administered as the calcium salt.
This pharmacological active derivative is spontaneously and enzymati-
cally catalyzed converted to its inactive lactone exhibiting higher lipo-
philicity compared to the educt [51,52]. Even if taken up in a higher
concentration, no difference was observed comparing accumulation of
the lactone in HCAEC and HCASMC. Other known statin uptake trans-
porters including OATP1B1 andOATP1B3 [53]were not detected in cor-
onary artery cells (data not shown). Our assumption is further
supported by enhanced cytotoxicity and transport of atorvastatin in
cells overexpressing OATP2B1. We did not test the inﬂuence of inhibi-
tion or knock-down of endogenous OATP2B1 on atorvastatin efﬁcacy
which is a limitation of our study. With respect to all herein reported
statins we also observed inhibition of OATP2B1 activity by cerivastatin
and simvastatin. However, the effective concentration of both statins
was higher than 50 μM, indicating that the observed antiproliferative ef-
fect of those statins ismore likely a result of passive diffusion than of ac-
tive transport by OATP2B1. Interestingly, mevastatin stimulated the E1S
uptake of OATP2B1, which may be explained by different afﬁnity sites
for E1S [54]. Nevertheless the moderate lipophilicity of mevastatin
may contribute to the detected unspeciﬁc cellular effects.
Taken together the data suggest that endogenous expression of
OATP2B1 is a determinant of cellular uptake andmay therefore be a pre-
clinical tool to identify substances with enhanced cellular accumulation
in muscle cells. An often used in vitro method to identify competitive in-
hibitors and thereby substrates are transport inhibition studies using
overexpressing cell lines and radiolabeled model substrates. Using
MDCK II cells overexpressing OATP2B1 and [3H]-estrone-3-sulfate we
screened a variety of cytostatics for their interaction with OATP2B1.
This approach revealed teniposide as a potent inhibitor of OATP2B1
in vitro. In order provide evidence, that teniposide is not only an inhibi-
tor, but also a substrate of OATP2B1 we performed proliferation assays
thereby assessing an indirect measure of enhanced cellular accumula-
tion. From a pharmacokinetic point of view compared to atorvastatin
and paclitaxel, teniposide is a moderate lipophilic substance suggesting
a higher inﬂuence of OATP2B1 on the observed antiproliferative activity.
In accordance with the assumption that enhanced intracellular accumu-
lation is linked to a better efﬁcacy of a substrate drug, we detected a sig-
niﬁcantly higher impact on cell proliferation by teniposide in presence of
artiﬁcial induced overexpression of OATP2B1 in smoothmuscle cells. Im-
portantly, comparing the effect of teniposide on proliferation of naïve
Fig. 6. Inﬂuence of teniposide on cell proliferation in naïve and OATP2B1 infected cells. (A) Naïve HCASMC were incubated 10 min or 48 h with increasing concentration of teniposide
(1 nM–100 μM) and proliferation was determined by BrdU ELISA. IC50 value (48 h) was calculated by non-linear regression. (B) Proliferation was determined by BrdU ELISA 48 h after
incubating naïve HCASMC and HCAEC with 1, 10, or 100 nM for 10 min (*p b 0.05, Student's t-test). (C) Uptake of [3H]-E1S in presence of teniposide (1, 10, 100 nM) was determined
in HCASMC 48 h after infection with 50 pfu/cell Ad-OATP2B1 (*p b 0.05 One-way ANOVA). (D) Cell proliferation was determined by BrdU ELISA 48 h after treatment. HCASMC were in-
cubated for 10 min with 10, and 100 nM teniposide (*p b 0.05, Student's t-test Ad-lacZ vs Ad-OATP2B1). Data are presented as mean ± SD of at least n = 3 experiments conducted in
triplicates.
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cells revealed higher sensitivity of HCASMC to teniposide compared to
HCAEC thereby further supporting our hypothesis that OATP2B1 modu-
lates cellular uptake and pharmacological activity.
5. Conclusion
We identiﬁed the HMG-CoA reductase inhibitor atorvastatin as a
candidate drug to be used on drug‐eluting stents, which exhibits higher
activity in smooth muscle cells. Based on the herein reported data the
enhanced muscle cell targeting is associated with higher endogenous
expression of the atorvastatin uptake transporter OATP2B1 in these
cells. As a determinant of pharmacokinetics of compounds used in the
microcompartment of the vessel wall this transporter may therefore
be a preclinical tool suitable to identify substances for the use on drug
delivery devices, as shown for teniposide.
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a b s t r a c t
The pharmacodynamics of the loaded compounds deﬁnes clinical failure or success of a drug-eluting
device. Various limus derivatives have entered clinics due to the observed positive outcome after stent
implantation, which is explained by their antiproliferative activity resulting from inhibition of the cy-
tosolic immunophilin FK506-binding protein 12. Although pimecrolimus also binds to this protein, pi-
mecrolimus-eluting stents failed in clinics. However, despite its impact on T lymphocytes little is known
about the pharmacodynamics of pimecrolimus in cultured human coronary artery cells. We were able to
show that pimecrolimus exerts antiproliferative activity in human smooth muscle and endothelial cells.
Furthermore in those cells pimecrolimus induced transcription of interferon-inducible genes which in
part are known to modulate cell proliferation. Modulation of gene expression may be part of an inter-
action between calcineurin, the downstream target of the pimecrolimus/FK506-binding protein 12-
complex, and the toll-like receptor 4. In accordance are our ﬁndings showing that silencing of toll-like
receptor 4 by siRNA in A549 a lung carcinoma cell line reduced the activation of interferon-inducible
genes upon pimecrolimus treatment in those cells. Based on our ﬁndings we hypothesize that calcineurin
inhibition may induce the toll-like receptor 4 mediated activation of type I interferon signaling ﬁnally
inducing the observed effect in endothelial and smooth muscle cells. The crosstalk of interferon and toll-
like receptor signaling may be a molecular mechanism that contributed to the failure of pimecrolimus-
eluting stents in humans.
& 2016 Elsevier B.V. All rights reserved.
1. Introduction
The natural occurring cytotoxic macrolide sirolimus (rapamy-
cin) and the anti-cancer drug paclitaxel were the ﬁrst compounds
used on drug-eluting stents resulting in a signiﬁcant reduction of
in-stent restenosis rates after stent implantation (Garg and Ser-
ruys, 2010; Moses et al., 2003; Stone et al., 2007). Supported by
experimental studies in animals and humans identifying in-
ﬂammation as one of the major driving forces for development of
in-stent restenosis after bare metal stent implantation (Kornowski
et al., 1998; Okamoto et al., 2001), it became evident that the
clinical success of sirolimus is not only based on the suppression of
smooth muscle cell proliferation, but also on the reduction of in-
ﬂammatory processes in the vessel wall (Guerra et al., 2014).
Sirolimus is assumed to bind to the cytosolic immunophilin
FK506-binding protein 12 (FKBP12) thereby inhibiting the mam-
malian target of rapamycin (mTOR) and preventing the degrada-
tion of the cell-cycle regulator p27kip which in turn regulates mi-
gration and proliferation of vascular smooth muscle cells (Martin
et al., 2004).
On the basis of the immunosuppressive function sirolimus was
origin for further pharmacological developments leading to the
evaluation of a variety of limus drugs to be loaded on drug-eluting
stents. While everolimus and zotarolimus have been shown to be
clinical efﬁcient and safe, other limus compounds failed during
development (Barbash et al., 2014; Chevalier et al., 2013; Tam-
burino et al., 2009). One of those is the macrolide derivative pi-
mecrolimus (SDZ ASM981). This molecule has been ﬁrst described
as potent anti-inﬂammatory and immunomodulatory drug (Mro-
wietz et al., 1998) and was ﬁnally approved for the topical treat-
ment of exfoliative skin diseases (Elidels cream, Novartis Phar-
maceutical Corp., East Hanover, N.J., USA) (Luger et al., 2001).
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/ejphar
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Regarding the use of this molecule in cardiovascular diseases
preclinical studies using pimecrolimus-eluting stents in a porcine
coronary model revealed the promising reduction of neointima
formation accompanied by complete endothelialization of the
stent struts (Berg et al., 2007; Waksman et al., 2007). Based on
those preclinical ﬁndings these stents were assumed to overcome
the problem of late stent thrombosis, an adverse event commonly
observed with the ﬁrst generation DES. Subsequently, Ormiston
and colleagues performed a clinical study showing excessive
neointimal formation in humans, which has been conﬁrmed by a
prospective multicenter study (Ormiston et al., 2009; Verheye
et al., 2009a). Taken together, pimecrolimus-eluting stents failed to
show clinical advantage even if preclinical data were more than
promising. Even though the controversy of preclinical and clinical
assessments may certainly be explained by species differences in
the role of inﬂammation in neointima formation little is known
about pharmacodynamics of pimecrolimus in cells of the human
coronary artery, as commented by Vorpahl et al. (2009).
Hence, the discrepancy of previous observations was basis of
the herein reported study investigating the cellular effects asso-
ciated with pimecrolimus treatment. Although pimecrolimus in-
duced the expression of interferon-inducible genes and slightly
inhibited the proliferation of smooth muscle and endothelial cells
as observed using human coronary cells these effects may not be
sufﬁcient to overcome the strong proliferative stimuli of stent
implantation.
2. Materials and methods
2.1. Materials
Human recombinant interferon-alpha2a (IFN-α) and inter-
feron-beta 1a (IFN-β) were purchased from Biomol GmbH (Ham-
burg, Germany) and Lucerna-Chem AG (Luzern, Switzerland), re-
spectively. Pimecrolimus was purchased from BioVision Inc. (Mil-
pitas, CA, USA), cyclosporin A and ruxolitinib were obtained from
Sigma-Aldrich (St. Louis, MO, USA). All other chemicals were
bought from Sigma-Aldrich (St. Louis, MO, USA) unless stated
otherwise.
2.2. Cell culture
Human coronary artery endothelial (HCAEC) and human cor-
onary artery smooth muscle cells (HCASMC) derived from different
donors were obtained from PromoCell GmbH (Heidelberg, Ger-
many) and cultured in their optimized media namely Smooth
Muscle Cell Growth Medium 2 and Endothelial Cell Growth
Medium MV (PromoCell). To compare the impact of pimecrolimus
on cell proliferation and gene expression we used cells of from
1 up to 4 individuals as indicated in the result section. For the
mechanistic studies we used cells isolated from one individual.
The human lung carcinoma cell line A549 (ATCCs, CCL-185™,
Washington, USA) was cultured in DMEM containing 10% FCS and
1% GlutaMAX™ (Gibco, Life Technologies, Carlsbad, CA, USA). All
experiments were conducted in technical triplicates and repeated
in three independent experiments. Cells were cultivated in a hu-
midiﬁed atmosphere at 37 °C supplemented with 5% CO2.
2.3. Cell viability assay and bromodeoxyuridine (BrdU) cell pro-
liferation assay
Cell viability and cell proliferation was determined in one in
vitro assay. At ﬁrst, cells were seeded in 96-well plates at a density
of 5103 cells/ well. After 24 h cultivation with the respective
growth media cells were starved for 24 h with basal media
containing only 0.5% FCS or 0.05% FCS for HCAEC or HCASMC, re-
spectively. After treatment with the compounds for 24 h BrdU
labeling solution was added to the medium and cells were cul-
tured for additional 24 h. Prior to the detection of the proliferation
status, cell viability was determined using the Fluorometric Cell
Viability Kit I obtained from Vitaris AG (Baar, Switzerland). The
reduction of the cell-permeable compound resazurin to the
ﬂuorescent red dye resoruﬁn is an indicator for the metabolic
activity of cells. After determination of viability, cells were washed
with PBS and proliferation was determined using the commer-
cially available colorimetric BrdU Cell Proliferation Kit (Roche,
Basel, Switzerland) according to the manufacturer's instructions.
Fluorescence or luminescence were detected using the microplate
reader Inﬁnites 200 Pro (Tecan, Männedorf, Switzerland). Cells
treated with the solvent served as control. Data are presented as
percent of control.
2.4. Interferon beta ELISA
The secreted amount of biological active human interferon beta
(IFN-β) in supernatants of HCAECs treated for 48 h with 10 mM
pimecrolimus or solvent control (DMSO) was determined using
the Human Interferon-β ELISA Kit obtained from Life Technologies
(Carlsbad, CA, USA). In brief, after treatment, the culture super-
natant was collected and concentrated using Pierce Concentrator
10 K obtained from Life Technologies followed by quantiﬁcation
using the above mentioned ELISA according to the manufacturer's
protocol. The reaction with the supplied color developer was
stopped after 30 min and the absorbance at 450 nm was detected
with the microplate reader Inﬁnites 200 Pro. The amount of hu-
man IFN-β in the supernatants was interpolated by linear curve
ﬁtting using the INF-β calibration curve (IU/ml). Secretion of IFN-β
is given as fold of DMSO-treated cells.
2.5. Small interfering RNA (siRNA) transfection
Knockdown of toll-like receptor 4 (TLR4) with Silencers Select
siRNA (s14195, Ambions, Life Technologies) was performed by
reverse transfection using DharmaFect transfection reagent 1
(Thermo Fisher Scientiﬁc, Reinach, Switzerland). First, the mixture
consisting of DharmaFECT 1 and TLR4-siRNA (ﬁnal concentration
of 25 pmol/ml) was prepared and added to each well of a 12-well
plate. After incubation for 30 min at room temperature 1.5105
cells/ well were seeded on top. In addition to TLR4-siRNA, cells
were transfected with Silencers Select GAPDH positive control
siRNA or negative Control No.1 siRNA (Life Technologies). Forty-
eight hours after transfection cells were treated with 10 mM pi-
mecrolimus for further 48 h and RNA was isolated. Cells trans-
fected with negative control siRNA served as reference and data
are presented in % of DMSO-treated cells.
2.6. RNA isolation and quantitative real-time polymerase chain re-
action (qRT-PCR)
Total RNA from cells was isolated with the NucleoSpins RNA
(Macherey-Nagel, Düren, Germany) in accordance to the manu-
facturer's instructions. After reverse transcription using the High
Capacity cDNA Reverse Transcription Kit (Life Technologies) gene
expression was carried out with the Viia7™ (Life Technologies).
Therefore, TaqMans gene expression assays from Life Technolo-
gies were used detecting interferon-induced protein with tetra-
tricopeptide repeats 1 (IFIT1, Hs01675197_m1), interferon-induced
protein with tetratricopeptide repeats 3 (IFIT3, Hs00155468_m1),
2′-5′-oligoadenylate synthetase 1 (OAS1, IFI4, Hs00973637_m1),
interferon regulatory factor 9 (IRF9, Hs00196051_m1), toll-like
receptor 4 (TLR4, Hs00152939_m1). The expression of 18 S rRNA
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(4310893E) was used as endogenous controls. The relative ex-
pression ratio was determined by the ΔΔCt comparative method
(Livak and Schmittgen, 2001).
2.7. Western blot analysis
Protein expression was determined in cells harvested in com-
mercially available RIPA buffer supplemented with 1% protease
inhibitor cocktail both obtained from Sigma-Aldrich. After quan-
tiﬁcation of protein content using the bicinchoninic acid assay
(Pierce, Thermo Fisher Scientiﬁc) 10 mg of each sample were se-
parated by SDS-PAGE and electro-transferred to nitrocellulose
membranes using a Tank blotting system (Bio-Rad Laboratories
AG, Cressier, Switzerland). Prior to overnight incubation with the
primary antibody membranes were placed in 5% FCS in TBS-T
(0.25 M Tris-base, 0.026 M KCl, 0.04% Tween 20) for 1 h. The an-
tibodies used were anti-pSTAT1 (5167, Cell Signaling, Cambridge,
UK), anti-STAT1 (sc-592) and anti-β-Actin (sc-1616) both from
Santa Cruz Biotechnology, Inc. (Dallas, Texas, USA) diluted in an
appropriate dilution in TBS-T supplemented with 0.5% BSA. After
several washing steps with TBS-T membranes were incubated with
the respective HRP-labeled secondary antibody for 1 h at room
temperature and luminescence was visualized using the ECL
Western blotting substrate (Pierce, Thermo Fisher Scientiﬁc Inc.).
Signals were digitalized with the ChemiDoc XRS system (Bio-Rad
Laboratories) and densitometry was conducted using Image Lab
4.1 software from Bio-Rad Laboratories.
2.8. Statistical analysis
Data are represented as mean7standard deviations (S.D.) from
at least three independent experiments conducted in technical
replicates. Graphs and calculations were performed using Graph-
Pad Prism© software (GraphPad Software, Inc., La Jolla, USA). Data
were statistically analyzed using one-way ANOVA followed by
Dunnetts post-hoc test to compare the mean values of more than
two groups. Data from interferon beta ELISA were analyzed by
Student's t-test to compare treated and non-treated cells. The re-
sults of qRT-PCR were analyzed a nonparametric test for not nor-
mally distributed samples. P values o0.05 were considered sta-
tistically signiﬁcant.
3. Results
3.1. Impact of pimecrolimus on cellular proliferation and viability
At ﬁrst, four individuals of each, human coronary artery smooth
muscle (HCASMC) and endothelial cells (HCAEC) were incubated
with increasing concentrations of pimecrolimus to determine
cellular behavior of human cardiovascular cells. As shown in
Fig. 1A 48 h of pimecrolimus treatment inhibited the proliferation
Fig. 1. Impact of pimecrolimus on cell behavior. Human coronary artery smooth muscle (HCASMC) and endothelial cells (HCAEC) of different individuals were incubated
with pimecrolimus (PM, 0.1 mM–25 mM) for 48 h. (A) Cell proliferation or (B) viability was determined by BrdU ELISA or ﬂuorometric resazurin, respectively. Data are
presented as mean7S.D. (log mM) in % of DMSO treated cells. n¼4 in triplicates, *Po0.05 One-way ANOVA PM vs. DMSO treated cells.
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of HCAEC or HCASMC at concentrations higher than 10 mM or
15 mM, respectively (mean in % of control7S.D., HCASMC
64.0720.7%, HCAEC 63.4715.9%, *o0.05 one-way ANOVA). Due
to solubility problems of the compound, an IC50 value was not
determined. However, pimecrolimus did not inﬂuence cell viability
(Fig. 1B). Taken together these observations suggested that pime-
crolimus has a cytostatic effect on the cells occurring at relatively
high concentrations.
3.2. Impact of pimecrolimus on calcineurin activation
Pimecrolimus and sirolimus bind to the immunophilin FKBP12
thereby modulating different downstream pathways. In order to
determine which pathway contributes most likely to the phar-
macodynamics of pimecrolimus in HCAEC we tested whether sir-
olimus or cyclosporine A, which binds the immunophilin cyclo-
philin A, are able to modulate the pimecrolimus effect. Therefore,
one individual of HCAEC was incubated with pimecrolimus in
presence of sirolimus or cyclosporine A. As shown in Fig. 2A sir-
olimus did not inﬂuence the antiproliferative activity of pimecro-
limus (mean proliferation in % of control7S.D., 59.175.0%).
However, concomitant treatment with the speciﬁc calcineurin in-
hibitor cyclosporine A, which itself did not inﬂuence proliferation
of the cells (Fig. 2B; 93.279.6%) signiﬁcantly enhanced the re-
duction of cell proliferation observed for pimecrolimus
(35.3716.5%; *Po0.05 one-way ANOVA). At this point we
hypothesized due to enhanced antiproliferative activity in pre-
sence of cyclosporine A that inhibition of the calcineurin-calmo-
dulin complex is at least in part playing a role in the cellular sig-
naling of pimecrolimus.
3.3. Expression of genes from the interferon pathway upon pime-
crolimus or sirolimus treatment
One of the signaling pathways modulated by the phosphatase
activity of calcineurin is that of interferons (IFN) (Kang et al., 2007;
Wang et al., 2012). Based on preliminary data of an RNA micro-
array (data not shown) comparing the gene expression pattern in
pimecrolimus treated and non-treated HCAEC and HCASMC sug-
gesting a modulation of type I interferon pathway, we determined
the expression of target genes by real-time PCR (involved genes
are depicted in Fig. 3). HCASMC and HCAEC, each cell type isolated
from four individuals, were treated with 10 μM pimecrolimus for
48 h and the expression of known target genes namely IFI4, IRF9,
IFIT3, and IFIT4 was investigated in both cell types (Fig. 3A and B).
Pimecrolimus enhanced the expression of the interferon-induced
protein with tetratricopeptide repeats 1 and 3 (IFIT1 and IFIT3) in
HCAEC (mean of mRNA expression7S.D.; 9.4274.13 and
3.6871.07, *Po0.05 Mann-Whitney test). Moreover, pimecroli-
mus induced the expression of interferon regulatory factor 9
(IRF9), and of 2′-5′-oligoadenylate synthetase (IFI4) (3.4372.21
and 3.5571.26, *Po0.05 Mann-Whitney test). Similar results
Fig. 2. Impact of immunophilin inhibitors. Human coronary endothelial cells (HCAEC) of one individual were incubated with 10 mM pimecrolimus (PM) in presence or
absence of (A) 1 mM sirolimus or (B) 1 mM cyclosporin A (CsA) for 48 h. Proliferation status was assessed by BrdU ELISA. Mean7S.D., n¼3 in triplicates, *Po0.05 One-Way
ANOVA. (C) Interaction of immunophilins cyclophilin A and FK506 binding protein 12 (FKBP12) with cyclosporin A, pimecrolimus or sirolimus and their subsequent
inhibition of calcineurin or mamalian target of rapamycin (mTOR). NFAT (nuclear factor of transcription); interleukin (IL)-2 and 4; tumor necrose factor (TNF)-α; interferon
(IFN)-γ.
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were observed for HCASMC. The pronounced effect on gene ex-
pression by pimecrolimus even increased with higher concentra-
tion (data not shown). No such inﬂuence on expression was de-
tected for sirolimus as determined in HCAEC of one individual
(compare Fig. 3C).
3.4. Pimecrolimus induced secretion of IFN-β
Our data revealed induction of genes known to be associated
with an activation of type I interferon receptors. In order to test
whether the observed transcriptional regulation is associated with
an increase in type I interferon secretion and thereby direct acti-
vation of the type I interferon receptor the amount of secreted IFN-
β was quantiﬁed in the supernatant of cardiovascular cells ex-
posed to pimecrolimus. As illustrated in Fig. 4A the im-
munosuppressant slightly increased the levels of INF-β released
into the supernatant of HCAEC (INF-β fold increase as mean7S.D.,
pimecrolimus vs. DMSO, 1.2270.05 vs. 1.0070.03, *Po0.05 Stu-
dent's t-test). No such effect was observed for HCASMC.
Fig. 3. Gene expression analysis upon compound treatment. (A) Human coronary artery endothelial cells (HCAEC) and (B) smooth muscle cells (HCASMC) isolated from
four individuals each were incubated with DMSO or 10 mM pimecrolimus. Gene expression of IFIT1 (interferon-induced protein with tetratricopeptide repeats 1), IFIT3
(interferon-induced protein with tetratricopeptide repeats 3, IRF9 (interferon regulatory factor 9), IFI4 (2′-5′-oligoadenylate synthetase), and 18S rRNA was determined by
qRT-PCR. Fold of mRNA expression is presented as single data points each representing the mean of one individual normalized to 18 S rRNA and related to the mean of the
DMSO control using the comparative ΔΔCt-method. Mean7S.D., n¼4 in technical triplicates, *Po0.05 Mann-Whitney test pimecrolimus vs. DMSO. (C) Endothelial cells of
one individual were incubated for 48 h with 1 mM sirolimus (SIR) or 10 mM pimecrolimus (PM) and gene expression of IFIT1, IFIT3, IRF9, IFI4, and 18S rRNA was determined
and analyzed using the ΔΔCt-method. Data are presented as mean7S.D., n¼3 in triplicates, *Po0.05 Kruskal-Wallis test compound vs. DMSO.
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3.5. Inﬂuence of type I interferons on cell proliferation
Treatment of HCAEC or HCASMC with IFN-β signiﬁcantly in-
hibited the proliferation of those cells (Fig. 5B and C). In detail,
HCASMC or HCAEC treated with 100 ng/ml exhibited a reduction
of the proliferation to 32.9713.9% or 65.2718.8%, respectively,
when compared to control treated cells (*Po0.05 One-way AN-
OVA). No such effect was detected using IFN-α. Importantly as
observed for pimecrolimus, INF-β treatment did not inﬂuence cell
viability still suggesting that the IFN-β pathway is part of the pi-
mecrolimus-induced inhibition of HCASMC and HCAEC.
3.6. Activation of Jak/STAT signaling upon pimecrolimus or IFN-β
treatment
Hitherto our data suggest that pimecrolimus induces target
genes of type I interferons. Although this may be in part explained
by the slight increase of INF-β secretion in presence of the im-
munosuppressant, the levels of INF-β detected in the supernatant
were far below those we used to test the inﬂuence on the cellular
behavior of cardiovascular cells. In order to test whether pime-
crolimus directly activates the type I interferon receptor complex
activation of intracellular signaling molecules was assessed.
Normally, binding of type I IFNs to the receptor activates an
intracellular signaling cascade that ﬁnally activates the transcrip-
tion of IFN target genes (compare Fig. 5A). For detection of STAT1
phosphorylation (pSTAT1) endothelial cells were incubated with
IFN-β or pimecrolimus for 15 min, washed and cultivated until
detection of pSTAT1. As shown in Fig. 4D IFN-β signiﬁcantly
induced phosphorylation of STAT1 as previously reported (Kalva-
kolanu, 2003), while pimecrolimus did not inﬂuence the phos-
phorylation status of this signaling molecule. In accordance are
ﬁndings showing that presence of the Jak1/2 inhibitor ruxolitinib
did not inﬂuence the antiproliferative activity of pimecrolimus as
observed in HCAEC of the same individual (proliferation in % of
control7S.D., PM vs. PM & ruxolitinib 59.175.0% vs. 61.575.6%).
Contrary, ruxolitinib abolished the effect of INF-β (84.1þ5.5% vs.
100.6þ4.8%,*Po0.05 One-way ANOVA, Fig. 4C). However, the in-
cubation with both compounds led to an increase of STAT1 ex-
pression with a maximal peak at 24 h (Fig. 5D).
3.7. Impact of TLR4 on interferon signaling cascade
It has previously been reported that the IFN-signaling pathway
is modulated by toll-like receptors (compare Fig. 5B). One receptor
known for its cross-talking is TLR4, and quantiﬁcation of mRNA
levels showed high expression of this receptor in HCAEC and
HCASMC (Supplemental S1). In the following experiments aiming
to test the inﬂuence of cellular knock-down of the TLR4 on the
pimecrolimus effect the immortalized cell line A549 was used,
since primary cells are difﬁcult to transfect (compare Fig. 6). Im-
portantly, A549 cells also exhibit the reduction of proliferation by
pimecrolimus and signiﬁcant levels of the TLR4 (Supplemental S2).
Even if the effect of pimecrolimus on expression of INF target
genes was less pronounced in those cells compared to that ob-
served in primary cells, the expression of IFI4 and IRF9 was on the
one hand signiﬁcantly induced by pimecrolimus and on the other
hand markedly reduced in presence of TLR4 siRNA (P¼0.05 Mann-
Fig. 4. Activation of type I IFN signaling pathway. (A) Human coronary artery endothelial cells (HCAEC) of one individual were incubated with 10 μM pimecrolimus (PM)
for 48 h and the release of IFN-β in cell supernatant was quantiﬁed using a speciﬁc ELISA. Data are presented as fold increase of DMSO treated cells, mean7S.D., n¼3 in
triplicates, nPo0.05 Student's t-test. (B) Activation of TLR4 cascade with subsequent IFN-β activation. (C) Endothelial cells of one individual were incubated with pime-
crolimus (PM) or IFN-β in presence or absence of 1 μM ruxolitinib. Proliferation was determined after 48 h by BrdU ELISA. Mean7S.D., n¼3 in triplicates, nPo0.05 One-way
ANOVA. (D) Endothelial cells of one individual were incubated with IFN-β or pimecrolimus (PM) for 15 min, washed with PBS and incubated for 48 h in growth medium.
Protein expression of phospho signal transducers of activation (pSTAT1), STAT1, and β-actin was determined in whole protein lysates using speciﬁc antibodies.
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Whitney test). Taken together those ﬁndings supported the notion
that pharmacodynamics of pimecrolimus is based on TLR4 acti-
vation cross talking to the IFN-signaling cascade.
4. Discussion
Understanding the molecular mechanisms involved in clinical
failure and/or success of a compound is a prerequisite for future
pharmacological developments. Pimecrolimus, which is an im-
munosuppressant in clinical use for topical application is one of
those compounds that failed during stent development. As
mentioned before, pimecrolimus-eluting stents were primarily
demonstrated to exert the highly preferred combination of in-
hibition of neointima formation and promotion of en-
dothelialization in the preclinical setting (Waksman et al., 2007).
However, those stents ﬁnally failed assessing clinical data in hu-
mans (Verheye et al., 2009a, 2009b). It was aim of this study to
identify potential cellular mechanisms that may have contributed
to the observed performance of pimecrolimus-eluting stents in
humans.
First, we determined its impact on cell proliferation and ob-
served a concentration-dependent cytostatic effect. This ﬁnding is
in accordance with previous ﬁndings in HUVECs and human
Fig. 5. Impact of type I interferons on cell proliferation and viability. (A) Type I IFN-signaling pathway. (B,C) Human coronary artery smooth muscle cells (HCASMC) and
endothelial cells (HCAEC) of at least three individuals each were incubated with 10 or 100 ng/ml interferon (IFN-β) for 48 h and (B) proliferation or (C) viability was
determined by BrdU Elisa or Resazurin viability kit, respectively. Mean7S.D., n¼7, nPo0.05 One-way ANOVA.
Fig. 6. Impact of TLR4 on pimecrolimus-induced effects. (A) A549 were transfected with siRNA for 48 h and gene expression of IFI4 (2′-5′-oligoadenylate synthetase), IRF9
(interferon regulatory factor 9), IFIT1 (interferon-induced protein with tetratricopeptide repeats 1) was quantiﬁed after 48 h incubation with 10 mM pimecrolimus (PM). Data
are presented as mean 7 S. D. normalized to 18S rRNA, n¼4 in triplicates, pimecrolimus vs. DMSO (2^-ΔΔCt). (B) Expression of TLR4 (toll-like receptor 4) is presented as
mean 7 S. D. normalized to 18 S rRNA, n¼4 in triplicates, scrambled vs. TLR4 siRNA (2^-ΔΔCt), *Po0.05 Mann-Whitney test.
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coronary smooth muscle cells (Grassberger et al., 1999; Konig
et al., 2013). The lack of efﬁcacy in clinical studies with an un-
expected neointimal response may be due to the low anti-
proliferative potency of pimecrolimus in HCASMC accompanied by
issues of solubility at concentrations higher than 30 mM as ob-
served in our study. However, the successful ﬁrst generation drug-
eluting stent compound sirolimus also functions as a cytostatic in
those cells, suggesting that there are differences in molecular
mechanisms contributing to the observed clinical outcome. One
mechanism assumed to contribute to the high efﬁcacy of sir-
olimus-eluting stents is the modulation of calcium signaling ﬁnally
inﬂuencing cell proliferation (Konig et al., 2013). Therefore, the
failure of pimecrolimus-eluting stents may be a result of in-
effective substrate concentrations or is based on a distinct cellular
mechanism.
From a pharmacological point of view, the class of limus deri-
vatives exerts its effects by binding to immunophilins such as
FKBP12 or cyclophilin A thereby inhibiting distinct pathways.
While the pimecrolimus-FKBP12 complex is assumed to inhibit
the phosphatase activity of calmodulin-dependent calcineurin
(Grassberger et al., 1999), the sirolimus-FKBP12 complex is as-
sumed to reduce serine kinase activity of the mTOR complex (Vi-
lella-Bach et al., 1999). And even though sirolimus does not inhibit
calcineurin, it has been shown to suppress the activation of nu-
clear factor of activated T cells (Konig et al., 2013). Cyclosporine A,
another immunomodulatory drug commonly used in clinics, binds
to the immunophilin cyclophilin A thereby speciﬁcally inhibiting
the calcineurin-calmodulin pathway (Liu et al., 1991). Based on our
observation of enhanced antiproliferative activity in presence of
cyclosporine A, we hypothesized that the calcineurin dependent
pathway may be part of the cellular effect of pimecrolimus. Im-
portantly, pimecrolimus exhibits much lower afﬁnity to FKBP12
(Ki100 nM) compared to sirolimus (Ki0.2 nM) thereby poten-
tially explaining the lack of an additive effect in cells treated with
both compounds (DeCenzo et al., 1996; Grassberger et al., 1999).
Preliminary mRNA microarray data obtained in our laboratory
suggested an upregulation of genes involved in the IFN-signaling
pathway in pimecrolimus treated cells. This has been conﬁrmed by
real-time PCR showing a signiﬁcantly increased expression of the
interferon-inducible proteins IFIT1, IFIT3, and the 2′-5′-oligoade-
nylate synthetase IFI4, known to regulate the immune host de-
fense and cell proliferation (de Veer et al., 2001; Der et al., 1998).
In terms of interferon signaling, interferon-regulatory factor 9
(IRF9) plays a key role in this pathway. This regulatory protein
forms with pSTAT1/2 the functional complex IFN-stimulated gene
factor 3. This transcriptionally active complex binds response
elements located in promotor regions of many IFN-stimulated
genes, and initiates their transcription (Darnell et al., 1994). In
addition, IRF9 is assumed to exhibit divergent regulatory activity
in terms of proliferation or apoptosis strictly depending on the cell
type and/ or the stimulus. Although it has been reported that INF-
β stimulated cancer cells are more susceptible to p53-dependent
apoptosis (Takaoka et al., 2003), after vascular injury IRF9 and
therefore the ISGF3 has been reported to be involved in neointima
formation (Zhang et al., 2014). Findings from Zhang and colleagues
showed that growth factor stimulated proliferation and migration
depends on IRF9.
Based on the herein reported data, it may be assumed that the
observed antiproliferative activity of pimecrolimus is associated
with secretion of type I interferons. Human type I interferons
namely INF-α and INF-β are primarily known for their function in
the innate immune response to viral infections, but are also reg-
ulators of different cellular processes including proliferation. In-
deed, type I interferons and particularly IFN-β are known to
modulate proliferation of smooth muscle and endothelial cells (da
Silva et al., 2002; Erdmann et al., 2011; Sano et al., 2015). The
observed difference in cellular response to INF-α (increased pro-
liferation) compared to INF-β (reduced proliferation) in the herein
reported study may be explained by differences in receptor afﬁ-
nities. As it has been shown that cellular signaling at least for IFN-
α subtypes are associated correlated to the binding afﬁnity to the
interferon receptor (Aguet et al., 1984). No difference in response
was observed treating the cardiovascular cells with IFN-β, which is
in accordance with ﬁndings from previous studies (Palmer and
Libby, 1992; Sano et al., 2015).
In order to determine whether pimecrolimus inﬂuences inter-
feron signaling by enhancing secretion of INF-β we quantiﬁed this
type I-interferon in the supernatant of treated cells. Even if se-
cretion of the interferon by HCAEC was slightly increased no such
effect was observed in HCASMC. Therefore, we assumed that the
activation of type I IFN inducible gene expression in pimecrolimus
treated cells is not attributable to a release of IFN-β with a sub-
sequent binding to its receptor. This is supported by the ﬁndings
on the activation of the Jak/STAT signaling cascade showing that
pimecrolimus did not induce a phosphorylation of STAT1. And
even though Rani et al. demonstrated that IFN-β can induce the
transcription of IRF9 without STAT activation (Rani et al., 2010),
there is evidence that calcineurin which is assumed to be inhibited
by pimecrolimus negatively regulates IFN response by modulation
of toll-like receptor mediated signaling pathways (Kang et al.,
2007).
In general, toll-like receptors are transmembrane proteins
regulating immune function and inﬂammation (Takeda and Akira,
2001; Uematsu and Akira, 2006). Especially TLR4 acts through
pathways leading to the production of pro-inﬂammatory cytokines
including TNFα and IFN-β (Akira, 2006; Bustamante et al., 2011). In
addition, inhibition of the calcineurin-calmodulin complex by
FK506 has previously been shown to interact with TLR4 signaling
at least in murine macrophages (Kang et al., 2007). In resting
macrophages, calcineurin interacts with TLR4, myeloid differ-
entiation protein 88 and TIR-domain-containing adapter-inducing
interferon-β (TRIF). In contrast if activated, TLR ligands or FK506
induce the dissociation of calcineurin from these proteins in
macrophages. Finally the release of TRIF is responsible for activa-
tion of the transcription factor interferon-regulatory factor
3 which results in enhanced IFN-β production and secretion in
activated macrophages (Doyle et al., 2002; Kawai et al., 2001). In
order to determine whether TLR4 is involved in the anti-
proliferative effect of pimecrolimus we studied whether knock-
down of TLR4 in the cancer cell line A549 diminishes the effect on
INF-target gene expression. Indeed, the expression of IFI4 and IRF9
was markedly reduced, suggesting that activation of TLR4 by pi-
mecrolimus may be involved. However, this slight reduction had
no impact on cell proliferation (data not shown). Therefore, the
impact of TLR4 on cell proliferation has to be further investigated
potentially employing alternative approaches. These ﬁndings
might lead to the assumption that pimecrolimus induced effect is
due to calcineurin inhibition by TLR4 mediated activation of type I
IFN-signaling. Importantly, the activation of pimecrolimus reduced
the TLR4 mRNA expression in HCASMC (Supplemental S2).
It seems noteworthy, that FKBP12 expression in resting smooth
muscle cells shows a much low abundance compared to plaque-
derived cells or those occurring in neointima (Bauriedel et al.,
2008), therefore the antiproliferative effect of pimecrolimus may
be signiﬁcantly higher in vivo, assuming that drug-eluting stents
are inserted in vascular plaques.
5. Conclusion
Clinical studies showed that drug-eluting stents coated with
limus compounds speciﬁcally inhibiting mTOR are superior
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compared to inhibitors of calcineurin (Qi-Hua et al., 2015; Tam-
burino et al., 2009). Even though preclinical studies suggested a
high impact of pimecrolimus on neointima formation clinical as-
sessments revealed a failure of pimecrolimus-eluting stents. We
provide evidence that pimecrolimus functions as an anti-
proliferative agent in vitro using vascular endothelial and smooth
muscle cells. These effects are assumed to be based on an inter-
action with its target protein calcineurin. However, the con-
centrations needed for the antiproliferative effect are rather high
and may be limited by solubility of the compound. In addition, we
observed an activation of interferon type I inducible genes, which
are part of a network regulating the immune host defense, apop-
tosis, and cell proliferation. Especially the interferon regulatory
factor 9 is controversy described in its efﬁciency to inhibit cell
proliferation. Nevertheless, siRNA knockdown of TLR4 suggested
an interaction of pimecrolimus with this cellular receptor by cal-
cineurin inhibition.
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Pimecrolimus increases the expression of interferon-inducible genes that modulate human 
coronary artery cells proliferation 
Janine Hussner1, Juliane Suenwoldt2, Isabell Seibert1, Daniel G. Gliesche1, Henriette Meyer zu 
Schwabedissen1 
1Institute of Biopharmacy, Department Pharmaceutical Sciences, University of Basel, Basel, 
Switzerland 
2University Medicine, Ernst Moritz Arndt University Greifswald, Center of Drug Absorption 
and Transport, Institute of Pharmacology, Greifswald, Germany 
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Figure S1 (A) mRNA expression of toll-like receptor 4 (TLR4) in human coronary endothelial cells 
(HCAEC) and smooth muscle cells (HCASMC) compared to A549 cells. Gene expression was 
determined in different passages and normalized to expression of 18S rRNA. Data are means ± S.D., n 
= at least 3 different passages. (B) Proliferation of A549 (lung carcinoma) was quantified after 48 h 
incubation with increasing concentration of pimecrolimus (0.1 – 25 log µM). Mean ± S.D. in % of 
DMSO treated cells. 
Figure S2 Gene expression of TLR4 after pimecrolimus treatment. Human coronary smooth muscle 
cells (HCASMC) isolated from four individuals were treated with DMSO or 10 µM pimecrolimus for 
48 h. Gene expression of toll-like receptor 4 (TLR4) and 18S rRNA was determined by qRT-PCR. Fold 
of mRNA expression is presented as single data points each representing the mean of one individual 
normalized to 18S rRNA and related to the mean of the DMSO control using the comparative ΔΔCt 
method. Mean ± S.D., n = 4 in technical triplicates. *P<0.05 Mann-Whitney test  
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Chapter 4
Conclusions and outlook 
One of the most concerning issues with implantation of drug-eluting coronary stents is the high 
incidence of late thrombosis associated with high mortality. Therefore, extensive research 
focused on the development of novel strategies to improve the long-term outcome of DES is 
necessary. One approach was to adapt stent material or the drug-eluting polymer to reduce the 
local hypersensitivity reaction that often occurs after stenting with drug release. Additionally, 
special emphasis was placed on identifying compounds or cellular mechanisms used for a more 
specific and/or efficient inhibition of SMC proliferation. However, as is often observed, 
although compounds demonstrated a high impact on neointima reduction, clinical assessments 
showed an unfavorable outcome. Hence, subsequent studies are necessary to address the 
underlying mechanisms. 
Stent material and drug polymer reduce the local hypersensitivity reaction 
It is a rational step to develop DES, where the selected stent material or polymer reduces the 
hypersensitivity reaction occurring with stent implantation. Stent strut thickness and a fast drug 
release often result in a pro-thrombotic surface. Current stent materials using platinum or 
chromium allow thinner stent struts and thus decrease the relative risk of clinical restenosis 50. 
Similar results are registered using degradable polymers. 
The release kinetics from stent polymer is an important characteristic often associated with the 
outcome. In our first study using a dual-loading drug technology based on a degradable PLLA 
polymer we detected a two-phase release profile with an initial burst release phase and slower 
release phase for both compounds. The initial burst release is characteristic for DES as shown 
particularly for the Cypher® sirolimus-eluting stent. The polymer elutes around 80% of the drug 
within the first 30 days. A longer drug release was associated with a better outcome as compared 
to a DES, which released its dose within 7 days 165. Furthermore, a high release of around 90% 
in the first 2 days is unfavorable since the high dose results in toxic drug concentrations or is 
inefficient due to fast metabolism and/or excretion 166, 167. 
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Dual-drug loading for a higher efficacy and safety of DES 
The regeneration of endothelial cells would decrease the incidence of stent thrombosis and thus 
avoid the long-term dual antiplatelet therapy that confers a substantial risk of bleeding 139. As 
most cytotoxic drugs do not exhibit a cell-specific effect, a pro-healing compound 
concomitantly used would provide an alternative strategy. 
Our developed dual-drug-eluting stent anticipates the inhibition of vascular SMCs without an 
impact on re-endothelialization. We therefore used an abluminal location of sirolimus and a 
luminal location of atorvastatin. Our goal was to combine the antiproliferative effect of 
sirolimus with the general observed effects of atorvastatin whereby minimizing the systemic 
exposure of sirolimus on ECs. Proliferation assays revealed that cellular effects were less 
pronounced in ECs than in SMCs. Thus, we suggest that luminal coating with atorvastatin is 
suitable to enhance re-endothelialization alongside a more targeted effect of sirolimus on SMCs 
with reduction of systemic toxicity. However, in vivo studies are warranted to prove the efficacy 
and safety of this dual-drug loading stent. 
Pharmacokinetics define pharmacodynamics of compounds 
Passive and active transport mechanisms play a crucial role in pharmacokinetics determining 
drug distribution to the target tissues and thus the biological activity of a compound. In the case 
of the vascular system where non-target (ECs) and target cells (SMCs) are in close vicinity, a 
coordinated distribution is necessary to obtain optimal drug concentrations in SMCs. 
When comparing the lipophilicity of statins one might predict the tissue retention time in the 
coronary artery after local application. Cerivastatin especially is a highly lipophilic compound 
compared to pravastatin whose hydrophilic properties result in rapid uptake by diffusion and 
high transport out of the cell. In accordance with this are findings that pravastatin failed to 
induce an effect on cell proliferation 156. Our studies provide evidence that endogenous 
expression of the drug transporter OATP2B1 is a determinant of statin effects in vascular cells. 
Using the transport activity of OATP2B1 as a screening approach may serve as a preclinical 
tool to identify compounds for an SMC-specific activity. 
One approach to obtain a cell-specific effect of candidate drugs is the modulation of their 
pharmacokinetics. It was the aim of our second study to prove the concept that changing the 
pharmacokinetics by adenoviral-induced gene expression can be used to enhance the cell-
specificity. We were able to show that the human drug transporter OCT1 increased the 
antiproliferative effect in SMCs using the promotor of transgelin (SM22α). Adenovirus-
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mediated overexpression of a drug transporter may be a potential strategy in combination with 
different delivery devices including bioresorbable stents or nanoparticles based on 
biodegradable polymers. 
In vitro studies are necessary to understand molecular mechanisms 
Although limus agents including sirolimus and everolimus exhibited a high impact on 
restenosis reduction, other compounds including tacrolimus and pimecrolimus failed to enter 
clinics. Since they share the same binding partner FKBP12 another downstream pathway may 
account for the contrary efficacy on SMC proliferation. As a part of this thesis we studied the 
effects of pimecrolimus in order to determine its pharmacodynamics in coronary cells. 
Importantly, we provide evidence that pimecrolimus functions as an antiproliferative agent in 
smooth muscle and endothelial cells. We believe that the inhibition of calcineurin with 
modulation of the type I interferon signaling pathway may explain the failure of this limus 
derivative. Thus, it is necessary to assess the pharmacodynamics of compounds especially in 
cells affected by vascular modeling processes after stenting. 
Our studies demonstrate different therapeutic approaches to improve the outcome of DES. 
Future developments are warranted which may combine different approaches involving novel 
drug candidates, polymers and stent surfaces. However, pharmacokinetics is still likely to be 
underestimated in stent technology but should be considered in future stent design since it often 
determines the biological activity of drugs in coronary cells. 
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